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Study of the efficacy of combination therapy based on 
bacteriophages for the control of infectious biofilms 
Abstract 
 
Pseudomonas aeruginosa is regarded as a “phenomenon of bacterial resistance”. 
This gram negative bacterium is responsible for a high percentage of mortality in the 
hospitals all over the world and its prevalence can be a consequence of important 
reasons, such as: intrinsic resistance determined by virulence factors; acquired 
resistance mechanisms that lead to a low susceptibility to antimicrobial agents; and the 
ability of P. aeruginosa to grow on any natural and artificial surfaces leading to the 
development of biofilms. The emergence of new strategies to control P. aeruginosa 
biofilms is becoming more evident due to their resistance to traditional treatments, and 
(bacterio)phages have been recognized as an attractive alternative for this problem. 
Nevertheless, despite the potential of phages as antimicrobial agents, it is well known 
that bacteria can quickly adapt and create new survival strategies and the emergence of 
phage-resistant phenotypes is inevitable. Thus, the combination of phage and antibiotic 
therapies could have potentially more benefits than just using phages and antibiotics 
alone. 
This work describes the combined effect of phages and antibiotics against 
planktonic cultures and biofilms of P. aeruginosa. The antimicrobial susceptibility of 
three reference strains of P. aeruginosa towards antibiotics belonging to four different 
action groups was initially evaluated and for this purpose, two important parameters 
were determined: Minimal Inhibitory Concentration (MIC) for planktonic cultures and 
Minimal Biofilm Eradication Concentration (MBEC) for biofilms. After that, phage 
infection assays were performed against cultures and biofilms of P. aeruginosa using 
four different phages from the Bacteriophage Biotechnology Group of the University of 
Minho. The efficacies of antibiotics and phages or both combined were evaluated in 
biofilms by viable cell enumeration and in planktonic cultures by measuring the 
absorbance (OD600nm). In general, all antibiotics tested showed little efficacy against 
biofilms which were also very tolerant to phage infection. The presence of degradative 
enzymes, such as beta-lactamase, and the survival of tolerant cells (persister cells) can 
explain the failure of antibiotics in reducing the cell numbers present in biofilms. In the 
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case of phage infection, the emergence of resistant phenotypes defective in LPS mutants 
can lead to long-term failure of these agents. 
In combined treatments, phages used together with ciprofloxacin caused total 
biofilm eradication. Also, other combinations resulted in interesting results. For 
example, the combination therapy of both phage phiIBB-PAP21 and amikacin resulted 
in approximately 3.66 log reduction of viable cells while individually, phage and 
amikacin only caused a 1.3 and 1.76 log reduction, respectively. The effectiveness of 
combined phages-antibiotic treatments can be due to a higher burst size, as observed 
with phage phiIBB-PAP21, when their host cells were exposed to antibiotics. Also, the 
higher biomass reductions observed when biofilms are exposed to a combined treatment 
suggest that phages can enhance the antibiotic penetration through matrix disruption, 
rendering cells freely available to be killed with antibiotics.  
Overall, the combination of phage and antibiotic enhances biofilm control; 
however the complex universe behind this synergistic interaction suggests that this is 
not always a linear process. Further studies should be conducted to complement and 
disclose this synergistic behaviour observed in the work described herein.  
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Avaliação da eficácia de terapias combinadas á base bacteriófagos 
no controlo de biofilmes infeciosos 
Sumário 
 
Pseudomonas aeruginosa é considerada um "fenómeno da resistência 
bacteriana". Esta bactéria gram-negativa é responsável por uma elevada percentagem de 
mortalidade nos hospitais de todo o mundo e a sua prevalência pode ser consequência 
de razões importantes como: resistência intrínseca determinada por vários fatores de 
virulência; mecanismos de resistência adquiridos que conduzem a uma baixa 
suscetibilidade aos agentes antimicrobianos e a capacidade de crescimento de P. 
aeruginosa em todas as superfícies naturais e artificiais que favorece ao 
desenvolvimento de biofilmes. A necessidade de novas estratégias de controlo de 
biofilmes de P. aeruginosa tem-se tornado mais evidente devido à sua resistência aos 
tratamentos tradicionais, e os bacteriófagos têm sido reconhecidos como uma alternativa 
atrativa para este problema. No entanto, apesar do potencial dos fagos como agentes 
antimicrobianos, sabe-se que as bactérias podem adaptar-se rapidamente e criar novas 
estratégias de sobrevivência e o aparecimento de fenótipos resistentes aos fagos é 
inevitável. Assim, a combinação de fagos com as terapias antibióticas pode ter 
potencialmente mais benefícios em relação á utilização isolada de fagos e antibióticos. 
Este trabalho descreve o efeito combinado de fagos e antibióticos contra culturas 
planctónicas e biofilmes de P. aeruginosa. A suscetibilidade antimicrobiana de três 
estirpes de referência de P. aeruginosa contra antibióticos pertencentes a quatro grupos 
de ação diferentes foi inicialmente avaliada. Para este fim, dois parâmetros importantes 
foram determinados: Concentração Mínima Inibitória (CIM) para culturas planctónicas 
e Concentração Mínima de Erradicação do Biofilme (CMEB) para os biofilmes. Depois 
desta etapa realizaram-se ensaios de infeção fágica contra as culturas e biofilmes de P. 
aeruginosa utilizando quatro fagos diferentes do Grupo de Biotecnologia de 
Bacteriófagos da Universidade do Minho. A eficácia dos antibióticos e fagos ou dos 
dois agentes combinados foi avaliada nos biofilmes pela enumeração de células viáveis, 
e nas culturas planctónicas pela medição da absorvência (OD600nm). Em geral, todos 
os antibióticos testados apresentaram pouca eficácia contra os biofilmes, os quais 
também foram muito tolerantes à infeção fágica. A presença de enzimas de degradação, 
 vi 
 
tais como a beta-lactamase, e a sobrevivência de células tolerantes (células persister) 
pode explicar a falha dos antibióticos sobre a redução do número de células presentes 
nos biofilmes. No caso da infeção fágica, o aparecimento de fenótipos deficientes na 
produção de LPS pode conduzir ao insucesso destes agentes a longo prazo. 
Nos tratamentos combinados, os fagos utilizados juntamente com ciprofloxacina 
causaram a erradicação total do biofilme. Também outras combinações demonstraram 
resultados interessantes. Por exemplo, a combinação de ambos fago phiIBB-PAP21 e 
amicacina resultou numa redução de células viáveis de cerca de 3,66 log, enquanto 
individualmente, o fago e amicacina só provocou uma redução de 1,3log e 1,76log, 
respetivamente. A eficácia da combinação fago-antibiótico pode ser devido a elevados 
burst size, tal como observado com o fago phiIBB-PAP21, quando o respetivo 
hospedeiro foi exposto a antibióticos. Além disso, as maiores reduções da biomassa 
observadas quando os biofilmes são expostos a um tratamento combinado sugerem que 
os fagos podem melhorar a penetração de antibióticos através de rutura da matriz, 
permitindo uma libertação das células para a ação dos antibióticos. 
Em geral, a combinação de fagos e antibióticos permite melhorar o controlo dos 
biofilmes; no entanto o universo complexo por trás desta interação de sinergia sugere 
que esta não é sempre um processo linear. Novos estudos devem ser realizados para 
complementar e divulgar este comportamento sinergístico observado neste trabalho. 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
 
Table of Contents 
 
Acknowledgements ........................................................................................................... i 
Abstract ............................................................................................................................ iii 
Sumário ............................................................................................................................. v 
List of Figures .................................................................................................................. ix 
List of Tables ................................................................................................................. xiii 
Abbreviations ................................................................................................................. xv 
 
Motivation and aim of the project................................................................................. 1 
 
Chapter 1: Review Literature ....................................................................................... 3 
1.1 Pseudomonas aeruginosa characteristics .......................................................... 3 
1.2 Pseudomonas aeruginosa virulence factors ...................................................... 3 
1.3 Clinical impact of Pseudomonas aeruginosa .................................................... 4 
1.1.1 Antimicrobial resistance of Pseudomonas aeruginosa .............................. 6 
1.4 Control strategies for Pseudomonas aeruginosa biofilms ................................. 8 
1.4.1 Antibiotics .................................................................................................. 8 
1.4.1.1 Categories of Antibiotics and mode of action......................................... 9 
1.4.2 Bacteriophages.......................................................................................... 10 
1.4.3 Antibiotics vs Bacteriophages .................................................................. 14 
1.5 Reference List ....................................................................................................... 16 
 
Chapter 2: Antimicrobial Susceptibility of P. aeruginosa ........................................ 21 
2.1 Background ........................................................................................................... 21 
2.2 Materials and methods .......................................................................................... 25 
2.2.1 Bacteria and growth conditions ...................................................................... 25 
2.2.2 Preparation of Antibiotics .............................................................................. 25 
2.2.3 Determination of Antimicrobial susceptibility ............................................... 25 
2.2.3.1 MIC determination .................................................................................. 25 
2.2.3.2 MBEC determination ............................................................................... 26 
2.2.4 Biomass Quantification .................................................................................. 26 
2.2.5 Microscopy analysis after BacLight
TM
 staining ............................................. 27 
2.2.6 Adhesion assays - Flow cell ........................................................................... 27 
2.3 Results and discussion .......................................................................................... 28 
2.3.1 Determination of the minimum inhibitory concentration (MIC) ................... 28 
2.3.2 Determination of the minimum biofilm eradication concentration (MBEC) . 29 
2.3.3 Evaluation of ciprofloxacin against adhered cells .......................................... 34 
2.4 Reference List ....................................................................................................... 37 
 
Chapter 3: Bacteriophage Treatment ......................................................................... 41 
3.1 Background ........................................................................................................... 41 
3.2 Materials and methods .......................................................................................... 41 
3.2.1 Bacteriophages.......................................................................................... 41 
3.2.2 Bacteriophage propagation, concentration and purification ..................... 42 
 viii 
 
3.2.3 Phage titration ........................................................................................... 42 
3.2.4 Infection of planktonic cells with phages phiIBB-PAP1, phiIBB-PAP21, 
phiIBB-PAA2, phiIBB-PAC23 ............................................................................... 43 
3.2.5 Infection of biofilm cells with phages phiIBB-PAP1, phiIBB-PAP21, 
phiIBB-PAA2, phiIBB-PAC23 ............................................................................... 43 
3.2.6 Statistical Analysis ................................................................................... 44 
3.3 Results and discussion .......................................................................................... 44 
3.3.1 Infection of planktonic cultures...................................................................... 44 
3.3.2 Infection of biofilms ....................................................................................... 45 
3.3.3 Evaluation of phages against adhered cells .................................................... 47 
3.4 Reference List ....................................................................................................... 49 
 
Chapter 4: Combined Treatment ................................................................................ 53 
4.1 Background ........................................................................................................... 53 
4.2 Materials and methods .......................................................................................... 54 
4.2.1 P. aeruginosa control by combined therapies using phages and antibiotics .. 54 
4.2.2 Zeta potential measurement of wild type strain and LPS mutants ................. 54 
4.2.3 One-step growth curve ................................................................................... 56 
4.3 Results and discussion .......................................................................................... 57 
4.3.1 Combined therapy in planktonic cultures....................................................... 57 
4.3.2 Combined therapy in biofilms ........................................................................ 58 
4.3.3 Antibiotic susceptibility and zeta potential of LPS mutant phenotypes......... 63 
4.3.4 Biofilm biomass ............................................................................................. 65 
4.3.5 Effect of antibiotics on the phage growth cycle ............................................. 67 
4.3.6 Efficacy of combined antibiotic-endolysins treatment................................... 68 
4.4 Reference List ....................................................................................................... 71 
 
Chapter 5: Main conclusions and Suggestions for forthcoming work .................... 75 
 
Chapter 6: Appendixes ................................................................................................. 79 
Appendix 1: Clinical breakpoints defined by EUCAST ............................................. 79 
 
 
 
 
 
 
 
 ix 
 
List of Figures 
 
Chapter 1 
 
Figure 1.1: LPS structure of P. aeruginosa ...................................................................... 4 
Figure 1.2: Schematic representation of stages of bacterial biofilm development. At 
stage 1, the bacterial cells attach reversibly to the surface, where weak forces 
prevalence. Next, at stage 2, the cells attach irreversibly, due mainly by exopolymeric 
substances, and as a consequence the cells lose their flagella-driven motility. At the next 
stages 3 and 4 the maturation of the biofilm occur, with the increment of biofilm 
architecture with formation of extracelular matrix. At stage 5 the dispersion of biofilm 
cells happen where single motile cells diffuse from the microcolonies ........................... 6 
Figure 1.3: Resistance mechanism mediated by phenotypic/persister variants in the 
biofilm. In the first part, antimicrobial treatment of bacterial biofilms leads to the 
eradication of part of the biofilm susceptible population (1). A small portion of 
phenotypic/a persister variant (represented as maroon bacteria) survive to the treatment 
(2) and are able to establish biofilm development after antimicrobial therapy is 
suspended (3).. .................................................................................................................. 8 
Figure 1.4: Diagrammatic representation of a typical bacteriophage structure .............. 11 
Figure 1.5: The life cycle of lytic bacteriophages: 1 – phage adsorption and DNA 
injection; 2 – host genome degradation; 3 - phage DNA replication; 4 – appearance of 
morphogenesis intermediates, including empty heads (proheads); 5 – packaging of 
phage DNA into capsids; 6 – phage assembly; 7 – lysis and release of progeny 
phage……………………………………………………………………………………13 
 
Chapter 2 
 
Figure 2.1: Schematic representation of the arrangement of components in the cell wall 
of P. aeruginosa and access of antibiotics ...................................................................... 24 
Figure 2.2: Assembly used in adhesion assays. .............................................................. 28 
Figure 2.3: Minimum Biofilm Eradication Concentration of antibiotics against P. 
aeruginosa strains: a) PA01; b) CECT 111; c) ATCC 10145. ....................................... 30 
Figure 2.4: LIVE/DEAD Bacligth
TM
 staining of P. aeruginosa CECT 111a) bacteria 
without antibiotic (control); b) treatment of bacteria with piperacillin; c) treatment of 
 x 
 
bacteria with ciprofloxacin. (Live cells – stained in green; dead cells – stained in 
red)……………………………………………………………………………………...32 
Figure 2.5: Visualization by electron microscopy of the elongation of P. aeruginosa 
cells in the presence of piperacillin. a) ATCC 10145, b) CECT 111, c) PA01 .............. 33 
Figure 2.6: Images of P. aeruginosa cells adhered over time to a glass surface after 
image processing by Sigma Scan Pro 5: a), b) and c) adhesion of cells; d) treatment with 
antibiotic ciprofloxacin. .................................................................................................. 35 
 
Chapter 3 
 
Figure 3.1: Phage infection of planktonic cells of P. aeruginosa strains PA01, CECT 
111 and ATCC 10145 with different concentrations of the respective phages. ............. 44 
Figure 3.2: Number of viable cells present in biofilms of P. aeruginosa strains PA01, 
CECT 111 and ATCC 10145 after exposure to different concentrations of the respective 
phages ............................................................................................................................. 46 
Figure 3.3: Images of P. aeruginosa cells adhered over time to a glass surface: a), b) and 
c) adhesion of cells; d) Infection of bacterial cells with phage phiIBB-PAP21. 1 – 
Bacterial cells; 2 – artefacts. ........................................................................................... 48 
 
Chapter 4 
 
Figure 4.1: Schematic representation of a possible synergy process between phage and 
antibiotic ......................................................................................................................... 53 
Figure 4.2: Disposable folded capillary cells used in zeta potential measurements....... 55 
Figure 4.3: Zetasizer Nano ZS used in zeta potential measurements ............................. 56 
Figure 4.4: Number of cells present in biofilm after exposure to a) Combined treatment 
phage-antibiotic during 6h and 24 h; b) Antibiotic treatment during 24h for CECT 111 
strain  A - amikacin 64mg/l; C – ciprofloxacin 4mg/l; P – piperacillin and T- 
tetracycline 256mg/l. ...................................................................................................... 59 
Figure 4.5: Number of cells present in biofilm after exposure to a) Combined treatment 
phage-antibiotic during 6h and 24 h; b) Antibiotic treatment during 24h for CECT 111 
strain A - amikacin 64mg/l; C – ciprofloxacin 4mg/l; P – piperacillin and T- tetracycline 
256mg/l . ......................................................................................................................... 59 
 xi 
 
Figure 4.6: Number of cells present in biofilm after exposure to a) Combined treatment 
phage-antibiotic during 6 h and 24 h; b) Antibiotic treatment during 24 h for PA01 
strain A - amikacin 64mg/l; C – ciprofloxacin 4mg/l; P – piperacillin and T- tetracycline 
256mg/l ........................................................................................................................... 60 
Figure 4.7: Number of cells present in biofilm after exposure to a) Combined treatment 
phage-antibiotic during 6 h and 24 h; b) Antibiotic treatment during 24 h for ATCC 
10145 strain A - amikacin 64mg/l; C – ciprofloxacin 4mg/l; P – piperacillin and T- 
tetracycline 256mg/l ....................................................................................................... 60 
Figure 4.8: Analysis of phage viability during synergy treatment. a) phage P1 with 
ciprofloxacin and amikacin; b) phage P21 with tetracycline and piperacillin; c) phage 
C23 with ciprofloxacin and amikacin. ............................................................................ 62 
Figura 4.9: Biomass quantification using Crystal Violet Staining: a) Treatment with 
antibiotic; b) combined treatment phage-antibiotic ........................................................ 66 
Figure 4.10: One-Step-Growth curve for phage P21 with antibiotic and without 
antibiotic ......................................................................................................................... 68 
Figure 4.11: Reduction of cells number presented in biofilms of P. aeruginosa strain 
PA01 after the exposure to antibiotic, endolysin and endolysin in combination with 
antibiotics. ...................................................................................................................... 69 
 
 
Chapter 6 
 
Figure A.1: Clinical breakpoints EUCAST for a) amikacin and b) ciprofloxacin against 
P. aeruginosa  ................................................................................................................. 80 
Figure A.2: Clinical breakpoints EUCAST for a) piperacillin and b) tetracycline against 
P. aeruginosa  ................................................................................................................. 81 
 
 
 
 
 
 xii 
 
 
  
 xiii 
 
List of Tables  
 
Chapter 1  
Table 1.1: Antibiotic families and mechanisms of action. ............................................. 10 
Table 1.2: Bacteriophages families. ............................................................................... 11 
 
Chapter 2 
Table 2.1: Values of Minimum Inhibitory Concentration (MIC) of antibiotics for the 
three strains of P. aeruginosa tested ............................................................................... 29 
Table 2.2: Values of Minimum Biofilm Eradication Concentration (MBEC) of 
antibiotics for the three strains of P. aeruginosa tested ................................................. 31 
 
Chapter 3  
Table 3.1: Characteristics of the phages ......................................................................... 42 
 
Chapter 4 
 
Table 4.1: Lytic spectra of phages against different P. aeruginosa wild type strains and 
mutant phenotypes .......................................................................................................... 55 
Table 4.2: MIC values for the combined treatment phage + antibiotic on planktonic 
cultures ........................................................................................................................... 57 
Table 4.3: Zeta potential measurements for wild-type strains and its LPS derivatives 
mutants ........................................................................................................................... 64 
Table 4.4: Life cycle parameters determined for phages used in this project ................ 67 
 
 
 
 
 
 
 xiv 
 
 
  
 xv 
 
Abbreviations 
 
ATCC - American Type Culture Collection 
CECT - Colleción Española de Cultivos Tipo 
CFU - Colony Forming Unit 
DNA - Deoxyribonucleic acid 
h - hours 
MIC - Minimum Inhibitory Concentration 
MBEC - Minimal Biofilm Eradication Concentration  
min - minutes 
MOI - Multiplicity of Infection 
MTA - Molten Top-Agar 
OD - Optical Density 
OSGC - One Step Growth Curve 
PEG - Polyethylene glycol 
PFU - Plaque Forming Unit  
RNA - Ribonucleic acid  
rpm -  revolutions per minute 
s - seconds 
TSA - Tryptic Soy Agar 
TSB - Tryptic Soy Broth 
 
 
 xvi 
 
 
Motivation and aim of the project 
 
1 
 
Motivation and aim of the project 
 
Pseudomonas aeruginosa is a gram-negative bacterium that can be found in two 
distinctive forms: planktonic form as unicellular organism; or sessile form, when 
attached to a substrate or a surface, leading to a biofilm formation. In the last years, P. 
aeruginosa has received a special attention because this microorganism has been 
described as a “phenomenon of bacterial resistance” and is responsible for a range of 
nosocomial infections or hospital–acquired infections. Actually, about 15% of the 
nosocomial infections worldwide, for example respiratory tract (in patients with cystic 
fibrosis), blood, urinary tract, ear, skin and soft tissue infections, are caused by this 
microorganism.  
The prevalence of P. aeruginosa in the hospital environment is becoming a 
critical issue, and for this reason, it is important to know what are the main factors 
involved. The emergence of these bacteria in clinical areas is a result of many factors, 
such as: intrinsic resistance determined by several virulence factors, including the 
presence of efflux systems, restricted membrane permeability and antibiotic degrading 
enzymes. Also, the acquired resistance mechanisms and the ability of P. aeruginosa to 
grow in any natural and artificial surfaces, like medical devices, leading to the 
development of biofilms, play an important role in this context. P aeruginosa is known 
to be tolerant to a variety group of antimicrobial agents, including b-lactams, 
aminoglycosides and fluoroquinolone antibiotics. Actually, infections caused by this 
microorganism become even more critical since the conventional treatments with 
antibiotics are failing because of an increasing resistance of the bacteria to many of the 
agents available on the market, and its broad spectrum of virulence factors. This 
unpleasant reality has led to an interest in using alternative strategies to combat 
infections caused by P. aeruginosa, one of which is the use of (bacterio)phages. 
Although there are few studies on biofilms, phages have shown significant potential in 
controlling this protective life form of bacteria. In fact, the use of phages presents 
important advantages over the use of antibiotics, in particular in clinical areas, because 
they don’t have lethal effects on eukaryotic cells. However, the emergence of bacterial 
resistance to phages is inevitable leading to a rapid conversion on resistant phenotypes.  
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For these reasons, the aim of the work presented in this thesis consists on 
developing a strategy to control biofilms formed by P. aeruginosa based in a 
combination of antibiotics and phages in the same antimicrobial solution. To 
accomplish this goal, the following approach was performed both for P. aeruginosa 
planktonic cultures and biofilms: 
1. Evaluation of the antimicrobial susceptibility using a set of antibiotics 
with distinct mechanisms of action; 
2. Phage efficacy studies to compare the two therapies and highlight some 
differences between them; 
3. Finally, study the synergy efficacy using the antibiotic-phage combined 
treatment. 
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Chapter 1: Review Literature 
 
1.1 Pseudomonas aeruginosa characteristics 
 
P. aeruginosa is a gram-negative and rod-shaped bacterium belonging to the 
class of Gamma Proteobacteria. It measures 0.5 to 0.8 µm in width by 1.5 to 3.0 µm in 
length, and almost all strains possess a single polar flagellum that allows motility. In 
terms of metabolism, it is an obligatory aerobe, because it prefers oxygen as the 
terminal electron acceptor, but in certain situations it can grow under anaerobic 
conditions using nitrate as the terminal electron acceptor 
[1,2]
.   
This bacterium is ubiquitous in soil and water and can be found in two 
distinctive forms: planktonic form, as a unicellular organism; and biofilm, when 
attached to abiotic surfaces or substrates. In terms of nutrition, P. aeruginosa has very 
simple requirements, and for this reason, growth factors and other complements are not 
necessary for its growth. The optimal temperature for growth is 37 degrees at a neutral 
pH. Nevertheless, it should be noted that P. aeruginosa is tolerant and resistant to a 
wide variety of physical conditions, like temperature, high concentrations of salts, 
disinfectants and antibiotics 
[1–3]
.  
 
1.2 Pseudomonas aeruginosa virulence factors 
 
Additional to the highest versatility in terms of nutrition and metabolism, P. 
aeruginosa is an opportunistic pathogen in humans and animals, displaying a variety of 
virulence mechanisms, derived from its intrinsic resistance which allow the 
establishment of the infection. These factors can be group in three main stages: 
adhesion, colonization and dissemination 
[3–5]
.  
For the development of these processes, the role of certain components is 
crucial. The most important one’s refer to enzymes such as proteases, elastases, and 
phenazine pigments such as pyocyanin which interferes with the tissue damage and 
destruction of certain immune cells 
[1,6]
. Also, the motility, the presence of pili, flagella, 
  Review Literature 
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lipopolysaccharides (LPS) and extracellular polymeric substances (EPS) constitute 
virulence mechanisms. For example, the LPS molecules (Figure 1.1) that are present on 
the outer membrane of this Gram-negative bacterium contribute to their pathogenicity, 
because they allow bacterial adhesion mediating the entry of bacteria into eukaryotic 
cells. In terms of structure and composition, the LPS of P. aeruginosa is very specific 
being composed of a lipid A, a core oligosaccharide divided in outer and inner cores and 
O-antigens that involve the A and B bands 
[7,8–11]
. Additionally, P. aeruginosa possesses 
several different export systems that are involved in the secretion of virulence factors, 
such as the injection of effector proteins directly into the cytoplasm of host cells that 
will interfere with the functioning of macrophages and neutrophils. Another factor that 
could be indirectly related to this virulence is the large and complexity genome of P. 
aeruginosa, which allows this microorganism to adapt and survive to different 
ecological niches. This could happen either through mutation of an existing gene 
product, or through the acquisition of a drug resistance plasmid 
[7,12]
. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: LPS structure of P. aeruginosa. Adapted from Atabek et al 
[7]
. 
 
 
1.3 Clinical impact of Pseudomonas aeruginosa  
 
Bioﬁlms are sessile microbial communities attached to a solid surface, in which 
the organisms produce a hydrated matrix of extracellular polymeric substances (EPS) 
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consisting of polysaccharides, proteins, nucleic acids, and lipids 
[13]
. Biofilms constitute 
an essential and protective lifestyle for bacteria in many different hostile and man-made 
environments, including dental plaques, water pipes, medical devices, and industrial 
systems 
[14,15]
. When the biofilm formation occur on indwelling medical devices (Figure 
1.2), this can lead to infection processes by detachment and dispersion of individual 
cells or aggregates of cells, resulting in serious damages on human tissues and organs. 
Additionally, the populations of bacteria within biofilms exhibit differences in the 
expression of surface molecules, antibiotic resistance, nutrient condition and virulence 
factors, and for these reasons, antimicrobial treatment that is sufficient to inactivate 
planktonic organisms is generally inadequate to inactivate biofilm organisms 
[13,15–18]
.  
In the hospital and community environments, the development of antimicrobial 
resistance plays a very important role in infections caused by P. aeruginosa biofilms. 
This bacterium is ubiquitous in clinical settings, it can be isolated from respiratory 
therapy equipment (endotracheal tubes used in mechanical ventilation), sinks and 
physiotherapy and even hydrotherapy pools. According to surveillance data collected by 
the European Centre for Disease prevention and Control (ECDC) organization, P. 
aeruginosa is considered the second most frequently isolated organism in cases of 
intensive care unit nosocomial infections. Additionally, according to ECDC, this 
bacterium was responsible for 30% of pneumonias and chronic lung infection in cystic 
fibrosis patients, 19% of urinary tract infections, and 10% of bloodstream infections, 
mainly in severe burn victims. In particular, in cases of nosocomial pneumonia there is 
a high rate of mortality and the treatment is difficult due the long-term of antibiotic 
treatment 
[5,19–21]
. 
Outside of the hospital environment, this microorganism can be found in 
swimming pools, whirlpools, hot tubs, contact lens solutions, home humidifiers, soil 
and vegetables 
[5,12,19,20]
. 
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Figure 1.2: Schematic representation of stages of bacterial biofilm development. At stage 1, the 
bacterial cells attach reversibly to the surface, where weak forces prevalence. Next, at stage 2, the cells 
attach irreversibly, due mainly by exopolymeric substances, and as a consequence the cells lose their 
flagella-driven motility. At the next stages 3 and 4 the maturation of the biofilm occur, with the increment 
of biofilm architecture with formation of extracelular matrix. At stage 5 the dispersion of biofilm cells 
happen where single motile cells diffuse from the microcolonies. Adapted from 
http://www.pasteur.fr/recherche/RAR/RAR2006/Ggb-en.html. 
 
 
1.1.1 Antimicrobial resistance of Pseudomonas aeruginosa  
 
Biofilm formation can be considered as a potential factor of antimicrobial 
resistance of P. aeruginosa, and there are important aspects that contribute for this 
situation. For instance, the mucoid exopolysaccharide matrix, that surrounds the biofilm 
cells, can act as an effective barrier that limits penetration of antimicrobial compounds 
[1,19,22]
. However, there are differences between certain classes of antibiotics in terms of 
biofilm penetration, because antibiotics like fluoroquinolones (such as, ciprofloxacin) 
have better penetration into biofilms, in opposite to aminoglycosides, which penetrate 
more difficultly 
[19,20]
. This can be related to the differences observed in delivery and 
transport of these molecules through the outer membrane of cells and since 
fluoroquinolones are small hydrophilic molecules, they pass easily through the aqueous 
channels on the membrane provided by porin proteins. On the other hand, the 
aminoglycosides (cationic antibiotics) promote their own uptake by binding to the 
negatively charged LPS on the outer surface of the membrane 
[23]
.  
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Furthermore, the biofilm population of P. aeruginosa is heterogeneous, which 
means that there are fast- and slow-growing cells. This happens because of gradients of 
nutrients and oxygen availability into the biofilm structure 
[19,23]
. The divergence of the 
cell population will create a fraction that is resistant to a range of mechanisms leading to 
a decrease in antimicrobial susceptibility of P. aeruginosa biofilms. This resistant 
subpopulation, also called persister cells, is a major source of reoccurring infections 
(Figure 1.3) 
[17,24]
. Also, the architecture and complexity of biofilms provides an 
appropriately environment for gene transfer and cell-to-cell signaling. This mechanism 
is called quorum sensing, and has been shown to play an important role in the 
expression of virulence factors, biofilm differentiation, cell attachment and detachment, 
through the activation of certain genes 
[7,23,25]
. 
In addition to biofilm formation, there are other factors which increase the 
resistance of P. aeruginosa to multiple antimicrobial agents. For example, the efflux 
pumps are responsible for extruding drugs, like antibiotic molecules, toxic metal ions, 
organic solvents and other ligands from inside the cell. In P. aeruginosa there are some 
important efflux pumps, such as the system MexAB-oprM that is responsible for 
extrusion of b-lactams, quinolones and a range of disinfectants; MexXY-oprM that 
extrudes aminoglycosides and MexEF-oprN that is responsible to extrudes carbapenems 
and quinolones 
[19,23]
.  
Other important mechanism of resistance of this bacterium is the modification of 
the primary target for antibiotics. In fluoroquinolones, one possible situation is the 
mutation in the gyrA gene that encodes the A subunit of the target enzyme, DNA 
gyrase, of this class of antibiotics 
[23,25]
.   
In terms of antibiotic uptake, the intrinsic resistance of P. aeruginosa plays also 
a central role in the rejection of some of these molecules. The own bacterial outer 
membrane, that possesses water filled channels, designated the transmembrane porins, 
constitutes a semi-permeable barrier to the uptake of antibiotics into the cell. For 
example, the OprF porin has a large exclusion limit and only allows small portions of 
Beta-lactams molecules moving inside the cells 
[8,9,23]
. Other examples include an 
expression of inactivating enzymes, like β-lactamases that will act on β-lactam 
antibiotics (for example piperacillin), degrading the β-lactamic ring present in these 
antibiotics and leading in this way to their inactivation 
[1,19,23]
.  
On the other hand, LPS, as described above, can interfere with antimicrobial 
resistance of P. aeruginosa, because when bacteria present a mutation in this structure, 
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(absence of O-specific chain for example) this can affect the antibiotic uptake, in terms 
of acceptance or rejection. In addition, there are some studies that reveal that the 
oligosaccharide portion of LPS structure may play an important position in the gating 
mechanism of porin proteins, such as OprF 
[7–9,26]
.  
 
 
Figure 1.3: Resistance mechanism mediated by phenotypic/persister variants in the biofilm. In the 
first part, antimicrobial treatment of bacterial biofilms leads to the eradication of part of the biofilm 
susceptible population (1). A small portion of phenotypic/a persister variant (represented as maroon 
bacteria) survive to the treatment (2) and are able to establish biofilm development after antimicrobial 
therapy is suspended (3). Adapted from Drenkard et al 
[19]
.
 
 
 
1.4 Control strategies for Pseudomonas aeruginosa biofilms 
 
This section will briefly review two strategies that can be used to control P. 
aeruginosa biofilms: antibiotics and bacteriophages.  
 
1.4.1 Antibiotics 
 
Antibiotics are chemical, natural or even synthetic substances that have been 
used for the last 70 years to treat patients who have infectious diseases, by preventing 
the growth of bacteria or their destruction. One important concept is that antibiotics are 
not active against viruses 
[27,28]
. Since the 1940s, the use of antimicrobial agents has 
been beneficial, because when prescribed and taken correctly they significantly reduce 
illness and death. However, often, these drugs have been used inappropriately and 
1 
2 
3 
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therefore, the antibiotics that are designed to kill infectious organisms become less 
effective causing emergence and selection of resistant and multiresistant bacteria 
[27,29,30]
. Antimicrobial resistance is nowadays one of the major threats to public health, 
mainly in health care settings. Every year, in the European Union, it is estimated that 
25.000 patients die because of serious resistant bacterial infections acquired in hospitals. 
Additionally, antibiotic resistance causes a direct impact to hospital and to the patient’s 
family: longer hospital stays increase of treatment costs; and frequently more expensive 
antibiotic drugs are used in treatments. There are also indirect factors that significantly 
affect the respective families and the society, such as: greater absenteeism at work,  
lower economic yield, decrease productivity by sequels and psychological and 
emotional changes 
[27,29,30]
.  
 
1.4.1.1 Categories of Antibiotics and mode of action 
 
Antibiotics can be categorised according to their action spectrum and mode of 
action. Regarding the first criteria, there are two types of antibiotics: narrow spectrum 
antibiotics and broad spectrum antibiotics. The first ones are specific for a specific 
bacterium and only prescribed when it is known which bacterium is causing the 
infection, and the second type refers to antibiotics that are used in case it is unclear 
which bacterium or bacteria  is/are causing the infection. Contrarily to the first type, this 
group of antibiotics also kill harmless bacteria due to their non-specificity 
[31]
.  
In terms of mode of action, antibiotics can be classified as bactericidal if they 
kill the susceptible bacteria; or bacteriostatic if they reversibly inhibit the growth of 
bacteria. In spite of bactericidal antibiotics being preferred, this does not mean that they 
are more effective than bacteriostatic 
[32]
. In this context, antibiotics can be classified in 
five major groups (Table 1.1), according to the physiological and metabolic functions in 
bacterial cell 
[33,34] 
.  
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Table 1.1: Antibiotic families and mechanisms of action. Adapted from Levy et al 
[34]
  
Mechanism of action Antibiotic families 
Inhibition of cell wall synthesis 
Penicillins; cephalosporins; 
carbapenems; daptomycin; 
monobactams; glycopeptides 
Inhibition of protein synthesis 
Tetracyclines; aminoglycosides; 
oxazolidonones; streptogramins; 
ketolids; macrolides; lincosamides 
Inhibition of DNA synthesis Fluoroquinolones 
Competitive inhibition of folic 
acid synthesis 
Sulfonamides; trimethoprim 
Inhibition of RNA synthesis Rifampin 
Other Metronizadole 
 
 
 
1.4.2 Bacteriophages 
 
Bacteriophages, also called phages, are viruses that kill bacteria and like other 
viruses they are obligate parasites, so they use the bacteria host to multiply and spread. 
Phages are ten times more numerous in the environment than bacteria, making them the 
most abundant ‘life’ forms on earth, with an estimated 1032 on the planet [35–37]. 
Bacteriophages cannot infect mammalian cells, but only specifically target bacteria.  
There are a variety of families of bacteriophage and according to the 
International Committee on Taxonomy of Viruses (ICTV) they are classified in terms of 
morphology and nucleic acid type (Table 1.2). A significant percentage of 
bacteriophages, about 96%, are distributed over three families that belong to the 
Caudovirales order: Myoviridae, Podoviridae and Siphoviridae (Figure 1.4) 
[1,36,38]
.  
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Table 1.2: Bacteriophages families. Adapted from Hanlon 
[36]
. 
Family Morphology Genome 
Corticoviridae 
Icosahedral capsid with 
lipid layer 
dsDNA 
Cystoviridae 
Enveloped, icosahedral 
capsids, lipids 
dsRNA 
Fuselloviridae 
Pleomorphic, envelope, 
lipids, no capsids 
dsDNA 
Inoviridae 
Rod-shaped with helical 
symmetry 
ssDNA 
Leviviridae Quasi-icosahedral capsids ssRNA 
Lipothrixviridae 
Enveloped filaments, 
lipids 
dsDNA 
Microviridae Icosahedral capsids ssDNA 
Myoviridae 
Non-enveloped , 
Contractile tail 
dsDNA 
Plasmaviridae 
Pleomorphic, envelope, 
lipids, no capsids 
dsDNA 
Podoviridae 
Non-enveloped , short non 
contractile tail 
dsDNA 
Rudiviridae 
Non enveloped, helical 
rods 
dsDNA 
Siphoviridae 
Non-enveloped , long  non 
contractile tail 
dsDNA 
Tectiviridae 
Icosahedral capsid with 
inner lipoprotein vesicle 
dsDNA 
 
 
Figure 1.4: Diagrammatic representation of a typical bacteriophage structure. Adapted from Harper et al 
[37]
. 
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Bacteriophages can exhibit one of two types of life cycle: virulent (lytic phages) 
or temperate (lysogenic phages). Virulent phages, the only ones allowed to be used in 
phage therapy, cause a rapid lysis and death of the host bacterial cell leading lead to a 
release of a hundreds of viral particles (Figure 1.5). The infection process starts from 
recognition and binding of the phage to the host by a specific receptor. This binding 
constitutes a critical stage, and when phage are irreversible connected to the host, the 
injection of genetic material of the phage occurs. Then, through the metabolism of the 
host, the DNA replication of the phage takes place, culminating in the formation of new 
phage particles. Subsequently, there is the packaging of the genome and recovery of 
phage particles. In the case of dsDNA phages, after the assembly, the phages present 
into the cytoplasm of bacterial host can produce enzymes that attack the bacterial 
peptidoglycan, leading to the instability of cell wall. These enzymes are designed lytic 
enzymes or endolysins and they have a therapeutic activity, mainly against gram 
positive bacteria. All of this process ends in lysis of the host bacteria and release of new 
phages that are able to infect other bacteria 
[36,39]
 .  
On the other hand, temperate phages spend part of their life cycle in a quiescent 
state called prophage, where their DNA is integrated into the host chromosome. This 
latent stage can be activated by specific stimuli, and then the phage can initiate a lytic 
mode infection 
[36,37]
. Phages with a lysogenic phage cycle can transfer fragments of 
host bacterial DNA, such as toxin-encoding or antibiotic resistance-mediating genes 
into other bacterial species by a mechanism of transduction producing new virulent 
strains 
[35,36]
 and therefore are not to be used therapeutically. 
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Figure 1.5: The life cycle of lytic bacteriophages: 1 – phage adsorption and DNA injection; 2 – host 
genome degradation; 3 - phage DNA replication; 4 – appearance of morphogenesis intermediates, 
including empty heads (proheads); 5 – packaging of phage DNA into capsids; 6 – phage assembly; 7 – 
lysis and release of progeny phage. Adapted from Kropinski [
39
].  
 
 
In addition, there are filamentous bacteriophages that have a different life cycle  
in which the infection is persistent, that is, there is no death of the host bacteria, but 
there is a continued production of viral particles 
[3,36,37]
. 
 
In a general context, phage therapy could be a potential approach in three 
different applications: 1) using phages as direct antibacterial agents, which, 
biotechnologically, could be fairly rapidly adapted for clinical applications; 2) isolating 
phage-encoded lytic enzymes that can be used as antibacterial agents alone or 
incorporated in the phage genome to be expressed during production of new phages by 
replication in their host cells. One example described in literature is the incorporation of 
Dispersin B (dspB) in phage T7 
[14] 
. Furthermore, phage polysaccharide depolymerases, 
specific enzymes found in the tail spikes of the phage baseplate, have been isolated and 
used to degrade the polysaccharide matrix, helping in this way phages in getting access 
to the biofilm cells 
[14,40]
. Other alternative, the most long-term application, but still very 
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promising is based in the  study of determinants of phage lytic mechanisms to identify 
novel drug targets 
[41,42]
.   
Currently, applications of phage therapy cover two main areas: clinical targeting 
their use to treat wounds, burns, chronic ulcers and respiratory tract infections, and food 
industry 
[43–45]
.  
 
1.4.3 Antibiotics vs Bacteriophages 
 
As any antimicrobial agents, antibiotics and bacteriophages have similarities, but 
also significant differences. First, phages only affect the target bacteria, while 
antibiotics act both on microorganisms and on the normal microflora of the patients and 
subsequently, at high concentrations, they may raise the risk of side effects. Phages 
have also a self-reproducing capability as long as their respective host is present, in 
opposite to antibiotics which require an administration of several doses since they are 
metabolized and eliminated from the body.  
Many authors have emphasized phage therapy as an alternative or adjuvant 
approach to antibiotics mainly due to the fact that their isolation, selection and 
production is relatively rapid contrarily to the time-consuming development of new 
antibiotics which involve several critical steps. However, this doesn’t necessarily mean 
that it is simple to isolate a highly virulent, lytic, broad-spectrum and non-transducing 
phage appropriate for effective therapy 
[36,45–47]
.  
A critical point that is inherent to both therapeutics is the appearance of bacterial 
resistance described already in section 1.3.1 for antibiotics. The development of 
bacterial resistance to phages happens due to a diversity of factors, such as: 
modification by mutation of the structure or exposure of host receptor molecules where 
phages adsorb; degradation of phage genome by DNAses after injection of the phage 
DNA into bacteria; inactivation of phages by the action of proteolytic enzymes present 
in biofilm matrix; entrapment of released phage particles in biofilm matrix 
[16,43,47,48]
.  
The combination of phages and antibiotics is of great interest and, a few studies 
have shown the potential of this combined treatment for the control of bacterial biofilms 
[49–52]
. One the few studies reported, describes that a phage-antibiotic combination 
resulted in a weaker biofilm matrix, mainly through the ability of phages to create pores 
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and channels to enter into the biofilms leading to a dispersion of a great part of biofilm 
cells which becoming more available to the action of the antimicrobial agent 
[50]
.  
On the other hand, it has also been described that combined treatments can 
decrease the mutation rate of the bacterial population, because a cell population hardly 
has, in the same genome, resistance mechanisms to survive both phage and antibiotic 
attack 
[49]
. Nevertheless, it can be considered that the mechanisms behind phage-
antibiotic synergistic action are still poorly explored.  
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Chapter 2: Antimicrobial Susceptibility of P. aeruginosa 
  
2.1 Background 
 
The selection of an antimicrobial agent and its dosage used in the treatment of P. 
aeruginosa is very important to prevent the growth of resistant bacteria, and this choice 
is crucial for the efficacy of process. Certain classes of antipseudomonal drugs that are 
frequently administered 
[1] 
and their mechanisms of action are described below: 
 
Amikacin 
Amikacin is an antibiotic of aminoglycosides family. In general, this antibiotic is 
administered to treat infections caused by gram-negative bacteria, such as 
Pseudomonas, Acinetobacter, and Enterobacter. In case of P. aeruginosa infections, 
due to its cationic nature, this antibiotic has the capacity to bind to LPS molecules 
(negative charged) and other anionic molecules such as DNA, RNA and phospholipids 
to access the interior of the cells. Inside the cells, amikacin acts on the 30S ribosomal 
subunit, preventing, in this way, the formation of an initiation complex with messenger 
RNA. Thus, the bacterium becomes unable to synthesize proteins that are vital to its 
growth. Also, amikacin can interfere with the cell membrane integrity 
[2–4]
.  
 
  
 
  
 
 
 
 
 
Amikacin 
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Ciprofloxacin 
Ciprofloxacin is an antibacterial agent of the fluoroquinolones class. This 
antibiotic has a broad spectrum activity, contrarily to amikacin, because it can act on 
gram-negative and gram-positive microorganisms. The main consequence of the 
bactericidal action of ciprofloxacin is the inhibition of the enzymes topoisomerase II 
(also called DNA gyrase) and topoisomerase IV. These enzymes are necessary for DNA 
replication, transcription, repair and recombination to bacterial cell. In P. aeruginosa, 
ciprofloxacin enters into the cell using porin protein OprF, and the positively charged 
piperazine ring at the C-7 position of the quinolone allows this molecule to interact with 
negatively charged phosphate groups of the phospholipid bilayer 
[2,5,6]
.  
 
 
Ciprofloxacin 
 
Piperacillin 
Piperacillin is a penicillin beta-lactam antibiotic. The antibacterial action of this 
antibiotic result from the binding to specific penicillin-binding proteins (PBPs) located 
inside the bacterial cell wall.  Subsequently, piperacillin inhibits the last point of 
bacterial cell wall synthesis. Alike ciprofloxacin, piperacillin has activity on both gram-
positive and gram-negative bacteria. However, it is mainly indicated to treat 
pseudomonal infections. In these bacteria, the diffusion of this anionic antibiotic is 
achieved by OprF protein in the outer membrane of the cell 
[2,7]
.  
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Piperacillin 
 
 
Tetracycline 
 This antibiotic has a bacteriostatic action against bacteria. Tetracycline belongs 
to tetracyclines family, and has a short action on the bacterial cell.  In gram-negative 
bacteria, its mechanism of action allows the inhibition of bacterial growth, because 
when it diffuses through the porin channels in the bacterial outer membrane as a 
positively charged molecule, it reversibly binds to the 30S ribosomal subunit and 
prevents the binding of tRNA to the mRNA-ribosome complex. As a consequence, the 
protein synthesis is affected 
[2,8]. 
 
 
Tetracycline 
 
The entry pathway (porin pathway or self-promoted pathway), the molecular 
characteristics of each antibiotic, and the diversity of intrinsic resistance factors of P. 
aeruginosa may dictate some important differences between antibiotics molecules, 
before the culmination of their action inside the cells. Figure 2.1, describes 
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schematically a process for the entry of antibiotics in P. aeruginosa cells in order to 
realize the major differences in the mechanism of reception of these molecules.  
 
 
Figure 2.1: Schematic representation of the arrangement of components in the cell wall of P. aeruginosa 
and access of antibiotics. Adapted  from 
[4]
 
 
There is a diversity of laboratory methods that can be applied in vitro to 
determine the susceptibility of bacteria to antimicrobial agents: broth microdilution test; 
disk diffusion test; antimicrobial gradient method (also called E-test) and automated 
instruments systems. In general, the majority of the methods available provide 
quantitative results. The Minimum Inhibitory Concentration (MIC), is defined as the 
lowest concentration of an antimicrobial that will inhibit the visible growth of a 
microorganism after an appropriate period of incubation 
[9]
.  
This chapter focuses on the main results obtained with the antimicrobial 
susceptibility tests against planktonic cultures (section 2.3) and biofilms (section 2.4).  
 
 
 
 
 Antimicrobial Susceptibility of P. aeruginosa 
25 
 
 2.2 Materials and methods 
 
2.2.1 Bacteria and growth conditions 
 
The bacterial strains that were used in this work were: PA01, CECT 111 and 
ATCC 10145. All strains were grown in Tryptic Soy Broth (TSB) medium. The solid 
medium was Tryptic Soy Agar (TSA): TSB + 1.2% w/v of agar. Both media were 
prepared according to the manufacturer’s instructions. Then, the media were sterilized 
by autoclaving at 121 °C for 15 minutes. 
 
2.2.2 Preparation of Antibiotics 
 
The standard powders of antibiotics were obtained from Sigma - Aldrich. Stock 
solutions were prepared and diluted according manufacturer’s recommendations and 
stored at -20 °C after filtration. During manipulation of antibiotics, these were always 
protected from light. 
 
2.2.3 Determination of Antimicrobial susceptibility 
2.2.3.1 MIC determination 
 
 To determine the MIC of the three P. aeruginosa strains (strains ATCC 10145, 
PAO1 and CECT 111) against the four antibiotics (amikacin, ciprofloxacin, piperacillin 
and tetracycline) the micro-broth dilution method was used. The experiment was 
performed according to the Clinical and Laboratory Standards Institute guidelines 
[10,11]
. 
Briefly, for each strain of P. aeruginosa used, two colonies were transferred 
from an overnight grown plate (from the first sub-culture, a second sub-culture on an 
appropriate agar plate was made) into 1 ml of TSB to approximate the density to 0.5 of 
the McFarland standard. This suspension, with an inoculum concentration of 10
8
 colony 
forming units per ml (CFU/ml) was then diluted to 10
6 
CFU/ml with the TSB medium. 
Serial two-fold dilutions of all the antimicrobial agents with the following 
concentrations (mg/l): ciprofloxacin (0.03125 - 1), amikacin (0.5 - 256), piperacillin 
(0.5 - 256), tetracycline (0.5 -256) were prepared with NaCl (0.9%) and then 100 µl of 
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each concentration were placed in 96-well microtiter plates. After, 100 µl of the 
suspension were added to the respective wells. TSB (100 μl) and 100 μl of 0.9% NaCl 
were used for the control experiments. Finally, the lowest concentration inhibiting 
visible growth after 20-24 h at 37 °C and 120 rpm was recorded as the MIC and the 
density (600 nm) was also measured. For these experiments three independent assays 
(each one in duplicate) were performed. 
 
2.2.3.2 MBEC determination 
 
Minimal Biofilm Eradication Concentration (MBEC) is defined as the lowest 
concentration of an antimicrobial agent that will inhibit the growth of a biofilm. Briefly, 
for each strain of P. aeruginosa, two colonies were transferred from an overnight grown 
plate (a second sub-culture on an appropriate agar plate was made from a first sub-
culture) into 1 ml of TSB to obtain a density of 1.0 in the McFarland standard (approx. 
3×10
8
 CFU/ml) and then diluted to obtain an inoculum of 10
7 
CFU/ml in TSB medium. 
After, 200 μl of P. aeruginosa cultures grown were added to 96-well microplates and 
incubated overnight at 37 °C and 120 rpm. After 24 h of biofilm formation, all medium 
was removed and the wells were washed with fresh TSB medium. Following that, 100 
μl of fresh TSB and 100 μl of antimicrobial solutions with different concentrations 
(256-64 mg/l) were added to the wells and control experiments were performed with 
100 μl of TSB and 100 μl of NaCl. The duration of MBEC assays was 24 h and after the 
microplates were washed twice with saline solution (0.9% NaCl) to remove all 
unattached bacteria. Fresh saline solution (200 μl) was added to each well, the biofilm 
scraped and the microplates were put in a water bath sonicator for 30 min. The number 
of viable cells present in biofilms before and after the treatment was determined by 
colony-forming unit (CFU) counts using the microdrop technique. For these 
experiments three independent assays (each one in duplicate) were performed. 
 
 
2.2.4 Biomass Quantification 
 
To quantify the total biomass attached to each well of 96-well microtiter plate, 
the crystal violet assay was used. This procedure consists of washing twice the biofilms 
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with a saline solution (0.9% NaCl), fixing with 200 µl of methanol (100%) (Merck) for 
15 min and after this period, the methanol was removed and the microplate allowed to 
dry at room temperature. Following that, 200 µl of crystal violet (1% v/v, Merck) is 
added to each well and the plate is let to stand still for 5 min. After, the wells were 
washed with water and allowed to dry at room temperature. Finally, 200 µl of acetic 
acid (33% v/v, Merck) was added to dissolve the stain attached to the biofilm, and the 
absorbance was read at 570 nm. For these experiments three independent assays (each 
one in duplicate) were performed. 
 
 
2.2.5 Microscopy analysis after BacLightTM staining 
 
P. aeruginosa cells were stained LIVE/DEAD® BacLight™ (Invitrogen 
Bacterial Viability Kit) 
[12] to access their viability according to the manufacturers’ 
specification. Briefly, an overnight culture  was adjusted to an OD600 of 0.4 – 0.5, and 
after that the cultures were added to a microplate and incubated for 2 h at 37 °C and 120 
rpm. After this incubation period the antibiotic solutions were added and allowed to act 
during 2 h at the same conditions as described above. The adhered cells were scrapped 
from the wells and put 20 µl in a microscope slide with 5 µl of LIVE/DEAD® 
BacLight
TM
 stain. The solution was mixed thoroughly and incubated at room 
temperature in the dark for 15 min. The fluorescence from both live and dead bacteria 
were observed simultaneously using a fluorescence microscope with a longpass 485 nm 
filter.  
 
2.2.6 Adhesion assays - Flow cell 
 
The cell adhesion assays were carried out using a laminar flow cell apparatus 
mounted on an inverted optical microscope (Nikon, Diaphot 300) coupled with a digital 
camera (CCD camera - Sony, AVC-D5CE) to capture images over time (Figure 2.2) 
[13]
. 
Before each assay, the entire system was washed with sterile water for 30 min and 
without recirculation. Then, in the same condition, TSB medium was passed through the 
system. 
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Cultures of P. aeruginosa were grown overnight at 37 ° C, centrifuged (7,000 
×g, 10 min, 4 ° C) and the pellet resuspended in TSB to an OD of about 0.5. After this, 
the suspension of P. aeruginosa was placed in the balloon of the system. During the 
feeding of the flow cell with bacterial cells, the system operated with recirculation of 
the suspension. When the whole surface was coated with cells, the feeding of cells was 
stopped and the washing with TSB medium was started without recirculation, to remove 
non adhered cells. After 30 min of washing, the antimicrobial agent was placed on the 
other balloon of the system, and the feeding started again. At the end of the tests, the 
entire system was washed. It is important to refer that the flow used was 0.124 ml/min. 
Subsequently, for image processing, a treatment using the software developed by 
Sigma (Sigma Scan Pro 5) was applied. 
 
 
Figure 2.2: Assembly used in adhesion assays. Adapted from Azeredo et al 
[13]
. 
 
 
 
2.3 Results and discussion 
2.3.1 Determination of the minimum inhibitory concentration (MIC) 
 
The micro-broth dilution method was used to determine the susceptibility of P. 
aeruginosa cells to specific antibiotics. The choice of this method is based in two main 
characteristics: it is a practical and reproducible method 
[9]
. Table 2.1 presents the MIC 
values obtained for each antibiotic tested and for each of the P. aeruginosa strains 
investigated. 
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Table 2.1: Values of Minimum Inhibitory Concentration (MIC) of antibiotics for the three strains of P. 
aeruginosa tested 
Antibiotic/strain MIC Range
  
tested
 
(mg per l)
  
CECT 111 PA01 ATCC 
10145 
Amikacin 0.5-256 4 4 4 
Ciprofloxacin 0.03125-1 0.125 0.125 0.125 
Piperacillin 0.5-256 8 16 8 
Tetracycline 0.5-256 8 8 16 
 
 
According to the results, it was possible to determine a MIC value to all 
antibiotics tested against the different bacterial strains studied. The results were very 
similar among the strains tested and showed that ciprofloxacin was the most effective 
antibiotic in eradicating bacteria in suspension, even at low concentrations. On the other 
hand, the strains were more resistant to tetracycline and piperacillin. In the case of 
tetracycline, its bacteriostatic action could explain the higher MIC values, because its 
binding to the ribosomal complex is only reversible, which makes its action very short 
[8]
. In the case of piperacillin, the higher MIC values can be due to the presence of 
inactivating enzymes, common in P. aeruginosa, such as beta-lactamases which  disrupt 
the amide bond of the b-lactam ring present in piperacillin 
[14]
.   
Overall, it is important to note that the results are consistent with clinical 
breakpoints defined by EUCAST for P. aeruginosa (Appendix 1 Figures A.1 and A.2) 
and all strains are present in the respective range of susceptibility described in literature 
[10,15–18]
.
 
 
 
2.3.2 Determination of the minimum biofilm eradication concentration 
(MBEC) 
 
The ability of antibiotics to disrupt the formation of biofilms (formed in 96-well 
microplates for 24 h) of the three strains of P. aeruginosa was explored (Figure 2.3).  
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Figure 2.3: Minimum Biofilm Eradication Concentration of antibiotics against P. aeruginosa 
strains: a) PA01; b) CECT 111; c) ATCC 10145. 
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Table  2.2: Values of Minimum Biofilm Eradication Concentration (MBEC) of antibiotics for the three 
strains of P. aeruginosa tested 
Antibiotic/strain MBEC 
Range
  
tested
 
(mg per l)
  
CECT 111 PA01 ATCC 
10145 
Amikacin 64-256 > 300 > 300 > 300 
Ciprofloxacin 32-128 >150 >150 >150 
Piperacillin 64-256 > 300 > 300 > 300 
Tetracycline 64-256 > 300 > 300 > 300 
 
 
The results confirm that biofilms can be up to 100 times more resistant to 
antibiotics than planktonic bacteria (compare Table 2.1, Table 2.2 and Figure 2.3). 
Furthermore, the results show that there are no significant differences between the 
susceptibility of the biofilms formed by the three strains to the tested antibiotics and that 
none allowed a total eradication of the established biofilms. Nevertheless, ciprofloxacin 
seems to be the most efficient antibiotic, reducing by approximately 6 logs the number 
of viable cells present in biofilms. These results are in agreement with those obtained by 
Abdi Ali and colleagues (2006) whom observed that the permeation of ciprofloxacin 
through alginate (component present in biofilm matrix of P. aeruginosa) was higher and 
had higher bactericidal activity in relation to aminoglycosides and beta-lactams 
antibiotics against P. aeruginosa biofilms 
[19]
. Furthermore, it is known that 
ciprofloxacin kills both rapidly dividing and slow-growing cells 
[20,21]
. 
Nevertheless, it is important to refer that even increasing ciprofloxacin 
concentration, there is always a 2 log of viable cells that remain on the biofilms, which 
probably correspond to a portion of persister cells that are tolerant to antibiotic action 
[20]
.  
In spite of significant structural differences between planktonic cells and 
biofilms, the behavior and efficiency of antibiotics was very similar, and again 
piperacillin was the less effective, with negligible effect on biofilms. Piperacillin is 
described to be only active on dividing cells, leaving intact all cells at the stationary 
phase of growth 
[21]
. To confirm, P. aeruginosa biofilms were stained with 
LIVE/DEAD® Baclight
TM
 (Figure 2.4).  
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Figure 2.4: LIVE/DEAD Bacligth
TM
 staining of P. aeruginosa CECT 111a) bacteria without antibiotic 
(control); b) treatment of bacteria with piperacillin; c) treatment of bacteria with ciprofloxacin (Live cells 
– stained in green; dead cells – stained in red). 
 
 
Staining with LIVE/DEAD BacLight
TM 
shows that ciprofloxacin treatments 
result in both dead (red) and live (green) cells, while piperacillin causes an inhibition of 
cell wall synthesis leading to an elongation of the cells, and has a poor bactericidal 
effect. All other strains were also subjected to piperacillin treatment (Figure 2.5).  
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Figure 2.5: Visualization by electron microscopy of the elongation of P. aeruginosa cells in the 
presence of piperacillin. a) ATCC 10145, b) CECT 111, c) PA01. 
 
 
As observed for CECT 111 (Figure 2.4), piperacillin caused an elongation of all 
other strains used in this work. This can be a survival strategy developed by bacteria 
against antibiotic molecules, because the cells stop dividing, but they still growth. 
Furthermore, it was also observed that the elongation effect increased with the 
concentration and contact time with the antibiotic (data not presented). 
Although after 24 h the viable biofilm bacteria decreased in number, more than 
10
4
 CFU/ml still remained after the treatment with amikacin at a concentration of 256 
mg/l. These results are contradictory to those reported by Gotto et al, where P. 
aeruginosa biofilms growing on Teflon catheters were eradicated already with a 64 
mg/l concentration 
[22]
.  
a) 
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Overall, there are several possible factors that can be behind the reduced efficacy 
of antibiotics towards P. aeruginosa biofilms, like the presence of a polymer matrix that 
act a a barrier for the penetration of antibiotics molecules; the presence of inactivation 
enzymes; the different microenvironment inside biofilm (metabolic heterogeneity) and 
the presence of dormant cells (also called persister cells) that are tolerant to antibiotic 
treatment and so, responsible for the survival of the biofilm population 
[21]
. In the work 
presented herein, in order to eradicate the biofilms formed it would be necessary to use 
antibiotic concentrations that exceed the peak serum concentrations.  
 
 
2.3.3 Evaluation of ciprofloxacin against adhered cells  
 
In order to study bacterial adhesion and the role of antibiotics as removal agents, 
the ability of antibiotics against adhered cells was evaluated using a parallel plate flow 
chamber with controlled hydrodynamic conditions and real time monitoring of the 
number of cells adhered over time 
[13,23]
. For this purpose, the adhesion assays were 
carried out with the strain CECT 111, using the most effective antibiotic – 
ciprofloxacin. In these assays, a supra-inhibitory concentration of ciprofloxacin was 
used (4mg/l - 32×MIC).  
Figure 2.6 presents images taken from the same sampling spot after 30 and 120 
min of adhesion of P. aeruginosa and after 40 min of treatment with ciprofloxacin.  
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Figure 2.6: Images of P. aeruginosa cells adhered over time to a glass surface after image 
processing by Sigma Scan Pro 5: a), b) and c) adhesion of cells; d) treatment with antibiotic 
ciprofloxacin. 
 
 
Ciprofloxacin treatment caused a significant reduction in the number of cells 
present in the glass surface, suggesting that it might have a positive role in the primary 
stage of biofilm formation. In spite of not having supportive data, it is suggested that the 
efficacy of ciprofloxacin in removing attached cells is related with modification of the 
cell surface properties stimulated by the antibiotic. This phenomenon could be 
confirmed by studies of the hydrophobicity and surface charge before and after 
exposure to the antibiotic. 
In clinical applications, these results can be very interesting, because the coating 
of medical devices with ciprofloxacin can contribute to a partial inhibition of biofilm 
formation.  
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Nevertheless, it is important to conduct additional studies, particularly to 
determine if a recolonization of the surface takes place.  
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Chapter 3: Bacteriophage Treatment 
 
3.1 Background 
 
P. aeruginosa have the ability to form dense and consistent biofilms with a low 
antimicrobial susceptibility. The emergence of pathogenic bacteria resistant to most 
currently available antimicrobial agents has become a critical problem in modern 
medicine. Thus, the development of alternative modalities has become one of the 
highest priorities in biomedical area to deal with infectious biofilms 
[1,2]
. The use of 
bacteriophages could be one of these modalities 
[3-5]
. The phage infection of biofilm 
cells is still not well understood  and various variables  involved in phage-host system 
can be determinant for its success, such as for instance, susceptibility of the biofilm 
cells to the phages, the availability of receptor sites and the production of 
polysaccharide-degrading enzymes by phages 
[6–8]
. Nevertheless, some phages are 
highly active towards biofilms, even mature ones 
[9]
.    
Similarly to the structure used in the previous section, this section will describe 
the main results obtained with the application of phages to cultures and biofilms of P. 
aeruginosa whereas the main objective is to evaluate the efficacy of phage therapy and 
compare it with the antibiotic therapy. 
 
3.2 Materials and methods 
 
3.2.1 Bacteriophages 
 
All phages used in this work have been previously isolated and belong to the 
bacteriophage biotechnology group collection 
[10,11]
. Table 3.1 presents their main 
characteristics.   
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Table 3.1: Characteristics of the phages  
Phage phiIBB- PA... Host bacteria Phage family and genus Phage genome data 
P21 CECT 111 
Siphoviridae 
MP22like 
 
P1 CECT 111 
Unclassified 
Myoviridae 
66.2 kb 
96 ORFs 
56% GC 
A2 ATCC 10145 
Podoviridae 
LUZ24like 
45,1 kb 
69 ORFs 
52% GC 
C23 PAO1 
Podoviridae 
LUZ24like 
45,1 kb 
68 ORFs 
52% GC 
 
 
3.2.2 Bacteriophage propagation, concentration and purification 
 
The plate lysis and elution method was used for phage production 
[12]
. Briefly, 
the method consists of spreading phage lysate, using a sterile paper strip, on a Petri dish 
containing a top-agar layer (3 ml Molten Top-Agar (MTA) - 30 g/l of TSB and 0.6% of 
agar) with 100 µl of the respective host bacteria. After overnight incubation at 37 °C, 3 
ml of SM buffer (5.8 g/l NaCl, 2 g/l MgSO4 × 7 H2O, 50 ml/l 1 M Tris, pH 7.5) was 
added to each dish and the plates were incubated during another 16-18 h stirring at 4 ° 
C. After this, the liquid and the MTA were placed on Erlenymer flasks to which 5.84 % 
(wt/vol) of NaCl was added, and after dissolved the flasks were placed under stirring 
during 1 h at 4 ° C, centrifuged (10 min, 10.000 ×g, 4 ° C), and 10% (wt/vol) of PEG 
8000 was added to the supernatant. This solution was incubated under agitation at 5 ° C 
for 16-18 h, centrifuged (10 min, 10.000 ×g, 4 ° C), and the supernatant discarded. The 
pellet was resuspended in 5-6 ml of SM buffer, chloroform 1:4 (vol/vol) was added, the 
tubes vigorously mixed during 30 s, and then centrifuged (15 min, 3500 ×g, 4 ° C). The 
phage, present in the upper aqueous phase, was carefully removed into new tubes, 
filtered (0.22 mm) and stored at 4° C.  
 
3.2.3 Phage titration 
 
Phage titer was determined using either the small scale drop method described 
by Mazzoco et al with some modifications or the double agar overlay plaque assay 
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formalized by Adams M 
[13,14]. The first method consists of adding 20 μl of serially 
diluted phage to 20 μl of the overnight grown host, followed by 15 min incubation at 37 
°C (120 rpm) and plating of 20 μl of sample on TSA agar plate. This method was only 
applied to phages phiIBB-PAP1 and phiIBB-PAP21 due to their plaque turbidity and 
size characteristics.  The double agar overlay plaque method consists in adding 100 μl 
of serially diluted phage, 100 μl of an overnight grown bacteria and 3 ml of MTA onto a 
TSA Petri dish. For both enumeration methods used, plates were incubated for 18 h at 
37 °C and after plaque forming units (PFU) were determined.  
 
3.2.4 Infection of planktonic cells with phages phiIBB-PAP1, phiIBB-
PAP21, phiIBB-PAA2, phiIBB-PAC23 
 
The procedure followed in this experience was similar to the protocol of MIC 
determination. Thus, after adjusting the cellular suspension to 0.5 (McFarland) with 
TSB, 100 μl of P. aeruginosa cultures (ATCC 10145, PA01, CECT 111), were put on 
the wells of a 96-well microplate. After, phage solutions (100 μl) with different 
concentrations (10
3
 – 108 PFU/ml) prepared in SM buffer, were added to the wells. 
Control experiments were performed with 100 μl of suspension and 100 μl of SM 
buffer. The duration of phage infection was 24 h. After this period, the OD (600nm) 
was measured. For these experiments three independent assays (each one in duplicate) 
were performed. 
 
3.2.5 Infection of biofilm cells with phages phiIBB-PAP1, phiIBB-PAP21, 
phiIBB-PAA2, phiIBB-PAC23 
 
Phage assays were performed similarly to the MBEC protocol. Briefly, after 
adjusting the OD600 to 1.0 (McFarland) with TSB, 200 μl of P. aeruginosa cultures 
(ATCC 10145, PA01, CECT 111), grown overnight at 37 °C and 120 rpm, were added 
to the wells of a 96-well microplate and incubated during 24 h. After 24 h of biofilm 
formation, the wells were washed with fresh TSB medium. Following that, 100 μl of 
fresh TSB and phage solutions (100 μl) with different concentrations (103 – 108PFU/ml) 
were added to the wells, or 100 μl of TSB and 100 μl of SM buffer in the case of control 
experiments. The duration of the phage infection was 24 h. Viable bacteria and phages 
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present in biofilms were determined by CFU and PFU enumeration. For these 
experiments three independent assays (each one in duplicate) were performed. 
3.2.6 Statistical Analysis 
 
In order to compare the amount of viable cells present in biofilms, it was 
performed an analysis of data variance (ANOVA single factor MS Office). This 
analysis was performed for a confidence interval of 95%. 
 
 
 3.3 Results and discussion 
3.3.1 Infection of planktonic cultures 
 
The infection of P. aeruginosa cultures with different concentrations of phages 
was evaluated (Figure 3.1).  
 
 
Figure 3.1: Phage infection of planktonic cells of P. aeruginosa strains PA01, CECT 111 and ATCC 
10145 with different concentrations of the respective phages. 
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The results revealed that none of the phage concentrations used decreased 
enough the density of the cultures. Furthermore, after 24 h of assay, it is well evident 
that the increase of phage solution does grant a higher density reduction. Of all phages 
tested, phage phiIBB-PAP21 was the most effective, reducing by approximately 50 
percent the initial density of the culture. This density reduction by phage phiIBB-PAP21 
was significantly different (p<0.05) from all other phages tested.  
Commonly, phage infection results in a density decrease which reaches a 
maximum after 5 to 7 h of infection. After this, the density rises mainly due to an 
emergence of resistant phenotypes 
[11]
. This may explain the poor phage efficacies 
observed since these experiments are performed during 24 h using the same conditions 
as for the MIC assays.  In same line and with the same conclusion, other study made by 
Kay M. (2010), reveal that after 24 h of phage infection planktonic culture of P. 
aeruginosa were barely affected by phage PB-1 
[15]
.  
 
 
3.3.2 Infection of biofilms 
 
Biofilms of P. aeruginosa were challenged with phage (Figure 3.2) and 
accordingly, phage phiIBB-PAC23 appears to be the least effective phage, with a 
negligible reduction in the number of viable biofilm cells (p> 0.05). This result suggests 
that the complex structure of biofilm can affect and limit the penetration of the phage to 
the cells. On the other hand, phage phiIBB-PAP21 causes a significant reduction (p 
<0.05) of viable cells present in the biofilm (about of 1.3 log). In spite of different 
conditions, Priscila (2011) observed similar rate of reduction with phage phiIBB-PAP21 
[12]
.  Surprisingly, the phage phiIBB-PAP1 showed greater efficacy in the control of 
biofilm cells compared to planktonic cells, with a 1.3 log reduction of cells present in 
biofilm of P. aeruginosa CECT 111.   
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Figure 3.2: Number of viable cells present in biofilms of P. aeruginosa strains PA01, CECT 111 and 
ATCC 10145 after exposure to different concentrations of the respective phages. 
 
 
Compared to antibiotics, it can be affirmed that phages had a lower efficacy in 
controlling biofilms of P. aeruginosa after 24 h of infection. Also, as it is possible 
observe in Figure 3.2, the viable cell numbers remained practically unchanged 
regardless of the different concentrations used. Contrarily to what was observed herein, 
Carson et al (2010) achieved a 4 log reduction in viable cells number of E. coli biofilms, 
after an infection of 24 h with T4 bacteriophage 
[16]
. Therefore, as with planktonic cells, 
one possible reason for this poor efficacy may be related with the quick emergence of 
LPS mutants phenotypes during a long period of phage infection since lack or loss of O-
antigen side-chains or any other conformational change can seriously affect phage 
adsorption to the bacterial surface 
[17,18]
.  
Additionally to these factors, with the exception of phage phiIBB-PAP1, all 
other phages lack exopolysaccharide (EPS) depolymerases which may contribute to an 
inefficient diffusion through the biofilm. The presence of depolymerases in phage 
phiIBB-PAP1 was confirmed by measuring over time the diameter of the halo around a 
phage plaque which is an indicator for the presence of phage-associated EPS 
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depolymerases. Since there was no halo around all other phages, it can be assumed that 
these phages lack depolymerases (data not shown).  
Verma et al (2010) has demonstrated the important role of phage associated 
depolymerase enzyme in the biofilm eradication of Klebsiella pneumonia 
[19]
. He 
observed that within a short period of time, the combination of depolymerase with a 
non-depolymerase phage caused a drastically reduction of cells in biofilms, compared to 
the individual application of the non-depolymerase phage. It is not very common to 
obtain isolate phages that express this type of enzymes. To overcome this difficulty 
many researchers have engineering commonly used cloning phages such as the 
circularized T7 and the filamentous phage M13 
[6,20,21]
 . The engineered phages reported 
by Lu and Collins (2007) allowed a reduction of bacterial bioﬁlm cells of E. coli by two 
orders of magnitude more than the non-enzymatic phage 
[6]
.  
Furthermore, it phage replication occurred within the biofilms, as expected, with 
phage plaque forming units increasing by more than 1 log at the end of the assay (data 
not shown).  
In general, phages, as well antibiotics, proved to have a minor role in controlling 
biofilms of P. aeruginosa. During the period of 24 h, the emergence of resistant 
phenotypes seems to be the main cause in its poor efficiency. 
 
3.3.3 Evaluation of phages against adhered cells 
 
Similarly to the tests performed with antibiotics, also the adhesion of cells and 
their infection with phage was evaluated. In this case, the phage phiIBB-PAP21 (10
8
 
PFU/ml) was used for these tests (Figure 3.3).  
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Figure 3.3: Images of P. aeruginosa cells adhered over time to a glass surface: a), b) and c) 
adhesion of cells; d) Infection of bacterial cells with phage phiIBB-PAP21. 1 – Bacterial cells; 2 – 
artefacts. 
 
 
In order to compare the two agents (phage and antibiotic), the same periods of 
time were analysed. Likewise ciprofloxacin, also phage phiIBB-PAP21 removed cells 
from the surfaces analysed. However, a higher amount of cellular debris was observable 
at the end of the phage treatment compared to antibiotics. Despite not having 
quantitative results, the removal rate of the cells by phages seems to be very close to the 
rate obtained with the antibiotic. It has been previously reported that a phage, specific to 
P. fluorescens, at a similar concentration had a reduction rate of adhered cells of P. 
fluorescens above 90% 
[9]
.  
These results suggest, once more, that phages and antibiotics can be controlling 
agents of the initial stage of biofilm formation, controlling biofilm formation on 
surfaces.  
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Chapter 4: Combined Treatment 
 
4.1 Background 
 
The combination of phages and antibiotics has taken the first steps in clinical 
research as a strategy for combating infectious biofilms. In spite of very recent, some 
studies have shown that the use of phages and antibiotics as adjuvants of each other is 
more effective in control biofilms, compared to their independent application 
[1]
. A 
research developed by Coulter L. (2012) demonstrated a greater efficacy of a 
combination of T4 phage and antibiotic trombamycin in the reduction of both biofilm 
mass and cells, compared to the use of phage and antibiotic alone 
[2]
.  
Nevertheless, there are still many questions about how this process is developed, 
particularly about the relationship that exists between the SOS response developed by 
bacteria against antibiotics and phage action, and how this affects the resistance 
evolution of bacteria when exposed simultaneously to both modalities agents (phage 
and antibiotic) - Figure 4.1 
[3–5]
. 
 
 
Figure 4.1: Schematic representation of a possible synergy process between phage and antibiotic. 
Adapted from Lu et al 
[5]
. 
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With the aim of improving the efficacy of phage and antibiotic therapy against 
P. aeruginosa biofilms, different phages were combined with different antibiotics and 
tested against planktonic cultures and biofilms.  
 
4.2 Materials and methods 
4.2.1 P. aeruginosa control by combined therapies using phages and 
antibiotics 
 
In combined therapy, all the structure and procedure of the treatments, based on 
the exposure of planktonic cells or biofilms to phage or antimicrobial agent alone, was 
followed. Antibiotics solutions were prepared on a 108 PFU/ml phage solution, creating 
in this way a combined solution, in which each phage was combined with each 
antibiotic used. In planktonic cultures, all the antimicrobial agents were tested with the 
following concentrations (mg/l): ciprofloxacin (0.03125 - 1), amikacin (0.5 - 256), 
piperacillin (0.5 - 256), tetracycline (0.5 -256). In the case of biofilm treatment, the 
antibiotic’s concentrations prepared in 108 PFU/ml phage solutions were: amikacin – 
64mg/l; ciprofloxacin – 4mg/l; piperacillin and tetracycline – 256 mg/l. The choice of 
this range of concentrations is based in the preliminary assays that were made. 
Combined experiments were also performed with antibiotics and endolysin 68gpLys, 
provided by Hugo Oliveira that is efficient against P. aeruginosa (unpublished data). 
The efficacy of the combined treatments was evaluated by enumeration of viable 
cells (CFU’s) and the determination of biofilm biomass by crystal violet assay, or by the 
measurement of absorbance (OD600nm) in the case of planktonic cultures. For these 
experiments three independent assays (each one in duplicate) were performed. 
 
4.2.2 Zeta potential measurement of wild type strain and LPS mutants 
 
Measurements of zeta potential were performed in order to obtain the surface 
charge characteristics of wild type and LPS mutant strains. For this, several LPS mutant 
phenotypes were provided by Prof. Joseph Lam (University of Guelph, Canada) and by 
Diana Priscila Pires (CEB, University of Minho). The susceptibility of these strains to 
the phages used in this work has already been evaluated (Diana P. P. Pires, unpublished 
data) and is presented below. 
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Table 4.1: Lytic spectra of phages against different P. aeruginosa wild type strains and mutant 
phenotypes 
 
P. aeruginosa ATCC 10145 P. aeruginosa PAO1 
wildtype M2 B2 B3 P2 wildtype wbpL rmlC wzy Rmd 
Phage 
phiIBB-
PA(…) 
A2 + - - - - + - - + + 
P21 + - + + + + + + + + 
C23 + - + + - + - - + + 
 
 
To perform zeta potential measurements, bacterial cells were grown overnight in 
TSB,  centrifuged at 10000 ×g for 10 minutes, and the cells were washed once with PBS 
buffer (pH of 7.0) and resuspended in PBS buffer. The bacterial suspension was 
introduced into Zetasizer Nano ZS (Malvern Instruments) - Figure 4.3 - and disposable 
folded capillary cells were used to measure the zeta potentials of the bacterial 
suspensions. The measurements were performed at 37 °C five times per strain, to ensure 
reproducibility. Finally, electrophoretic mobility was converted to zeta potential through 
the Smoluchowski equation 
[6]
.  
 
 
Figure 4.2: Disposable folded capillary cells used in zeta potential measurements. Adapted from [
6
] 
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Equation 4.1:    
       
  
           
   
z : Zeta potential;UE : Electrophoretic mobility; ε : Dielectric constant. ƞ : Viscosity. 
 
 
 
Figure 4.3: Zetasizer Nano ZS used in zeta potential measurements. 
 
 
4.2.3 One-step growth curve 
 
In this work, OSGCs were performed as described by Rahman M. et al. with 
some modifications 
[7]
. In brief, 10 ml of a mid-exponential-phase culture of bacteria 
(OD 600nm: 0.35) was harvested by centrifugation (7,000 ×g, 5 min, 4 ºC) and 
resuspended in 5 ml TSB medium. To this suspension, 5 ml of phage solution was 
added in order to have a multiplicity of infection (MOI) of 0.01 and phage was allowed 
to adsorb for 5 min at 37 °C and 120 rpm. The mixture was then centrifuged as 
described above, the pellet was resuspended in 10 ml of fresh TSB medium and the 
mixture was incubated at 37 ºC under agitation (120 rpm) . Two samples were taken 
every 5 min over a period of 30 min and every 10 min until the end of the assay (120 
min).  
In relation to the experiments with cells infected with antibiotic, the method was 
slightly different in the first part. That is, firstly cells were incubated overnight with 
antibiotic at a sub-MIC concentration (4 mg/L) at 37 °C and 120 rpm and in the 
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following day, cells were spun down (7,000xg, 10 min, 4 ºC), the antibiotic 
(supernatant) discarded, and the pellet washed twice with TSB. A fresh inoculum was 
incubated for 3 h and after that, the number of cells was counted using a neubauer 
chamber. After, the phage solution was prepared in order to have a MOI of 0.01, and 
from this point the rest of the method was followed as describe above. 
 
4.3 Results and discussion  
 
4.3.1 Combined therapy in planktonic cultures 
 
The effect of combined therapy in planktonic culture of PA01, CECT 111 and 
ATCC 10145 strains is presented in Table 4.2. 
 
Table 4.2: MIC values for the combined treatment phage + antibiotic on planktonic cultures  
 
 
The combination of phage phiIBB-PAP21 and all antibiotics show a strong 
enhancement of antibiotic killing leading to lower MIC values than when antibiotics 
alone were used (see Table 2.1). With phage phiIBB-PAP1 the reduction of antibiotic 
susceptibility was observed for all antibiotics with the exception of tetracycline. 
Conversely, phage phiIBB-PAC23 only enhanced antibiotic killing with piperacillin and 
combined phage-antibiotic assays with phage phiIBB-PAA2 did not result in any MIC 
reduction compared to antibiotics alone.  
Nevertheless, contrary to the results obtained in the phage infection, with 
combined treatment is already possible to get MIC values within the susceptible range 
defined by EUCAST clinical breakpoints, which means that all strains are susceptible to 
Antibiotic Strain + phage 
 
CECT + 
phiIBB-PAP1 
CECT + 
phiIBB-PAP21 
PA01 + 
phiIBB-PAC23 
ATCC + 
phiIBB-PAA2 
Amikacin 1 1 4 16 
Ciprofloxacin 0,0625 0,0625 0,125 0,25 
Piperacillin 2 2 4 8 
Tetracycline 16 4 32 32 
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the combined phage-antibiotic treatment. Additional, since it was possible define a MIC 
value for all strains, it is possible to conclude that after 24 h there is no development of 
resistance by the cells, which proves to be an innovative result in relation to the 
application of phages alone. Zhang et al (2011) also prove that the combination of 
phage and antibiotic potentiate the reduction in the survival of P. fluorescens 
populations 
[8]
.  
On the other hand, these results demonstrate in some way that the synergy 
between phage and antibiotics is not a simple phenomenon, since significant differences 
were found between the strains.  
Overall, some of these tested combinations proved to be good candidates for 
further testing for control of infectious biofilms. 
 
4.3.2 Combined therapy in biofilms 
 
In biofilm assays, the number of cells present in biofilms was evaluated in two 
distinct moments after the exposure to the combined treatment: 6 h after infection and 
24 h after infection (Figures 4.4 to 4.7). The choice of these two periods was to 
determine if the simultaneously action of phage and antibiotic allows the reduction of 
bacterial resistance after 6 h of treatment. In previous studies it was demonstrated that 
phage resistance appears after 6 h of infection 
[9]
.  
It is important to refer that since the antibiotics amikacin and ciprofloxacin 
showed the lowest MBEC values in MBEC assays, for these combined experiments the 
concentrations of these antibiotics used were inferior (see Materials and Methods) . The 
goal was to see if with the combined treatment maintains or exceeds the rate of efficacy 
while the antibiotic concentration is reduced. 
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Figure 4.4: Number of cells present in biofilm after exposure to a) Combined treatment phage-
antibiotic during 6h and 24 h; b) Antibiotic treatment during 24 h for CECT 111 strain  A - amikacin 
64mg/l; C – ciprofloxacin 4mg/l; P – piperacillin and T- tetracycline 256mg/l. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Number of cells present in biofilm after exposure to a) Combined treatment phage-
antibiotic during 6h and 24 h; b) Antibiotic treatment during 24 h for CECT 111 strain A - amikacin 
64mg/l; C – ciprofloxacin 4mg/l; P – piperacillin and T- tetracycline 256mg/l.  
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Figure 4.6: Number of cells present in biofilm after exposure to a) Combined treatment phage-
antibiotic during 6 h and 24 h; b) Antibiotic treatment during 24 h for PA01 strain A - amikacin 64mg/l; 
C – ciprofloxacin 4mg/l; P – piperacillin and T- tetracycline 256mg/l. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Number of cells present in biofilm after exposure to a) Combined treatment phage-
antibiotic during 6 h and 24 h; b) Antibiotic treatment during 24 h for ATCC 10145 strain A - amikacin 
64mg/l; C – ciprofloxacin 4mg/l; P – piperacillin and T- tetracycline 256mg/l.  
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As it is possible observe in Figures 4.4 to 4.7, between 6 h and 24 h of treatment 
there was, with the exception of the combination phage and piperacillin, no viable cell 
increase and under certain circumstances there was even a further decrease.  
An interesting and very promising result is related with the complete eradication 
of the biofilm, after 24 h when combining ciprofloxacin with the different phages. 
Furthermore, total eradication was already observed after 6 h of combined treatment 
between phage phiIBB-PAP21 and ciprofloxacin. Also, with the combined treatment 
the residual cells observed after ciprofloxacin treatment alone are eliminated. One of the 
possible explanations for this event is the action of phages on persister cells. This was 
observed by Pearl et al (2008), under a study about host-phage interaction, whom 
demonstrated that with lytic infection, persister cells from biofilms can be eliminated 
when they are submitted to their normal growth state 
[10]
. Possibly, the combination of 
phage and antibiotic can be, in a certain way, a stimulus for the reactivation of persister 
cells to normal growth. Furthermore, in this work the combination solution was 
performed using a very low concentration of the antibiotic ciprofloxacin (4 mg/l), which 
means that with this phage, the concentration of antibiotic needed to control biofilms of 
P. aeruginosa is much lower than when the antibiotic is used alone and for this reason 
the toxicity of the antibiotic can be reduced. This result can also have important effects 
in studies in vivo, because the maximum achievable concentration for ciprofloxacin in 
serum is in the range of 2-4mg/L 
[11]
. Moreover, these results demonstrate that there is a 
potential synergy between phage phiIBB-PAP21 and ciprofloxacin, and the value of the 
MBEC can be roughly reduced by using ciprofloxacin and phage at the same solution. 
In spite of using different bacteria, Ryan et al (2012) also observed an enhancement 
effect on biofilm eradication of E. coli combining cefotaxime with phage T4, observing 
a reduction from 256 to 32 mg/L of MBEC values 
[12]
.  
Regarding now the other combinations, the enhancement killing seems to be also 
significant (p<0.05) between phage phiIBB-PAP21 and amikacin, with more 2 log 
reduction of cells number, respectively compared to antibiotic treatment. Also, the 
phage phiIBB-PAA2 together with the antibiotic piperacillin can be a good choice to get 
a significant decrease of cells number (p<0.05). Nevertheless, with amikacin this phage 
does not appear to act synergistically because a greater number of cells were observed 
after 24 h, compared to treatment with antibiotic alone. On the other hand, the 
combination of any of the phages with tetracycline has not a significant effect on the 
reduction of viable cell numbers, presenting only a negligible effect on biofilms. In a 
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certain way, this result was expected, due the previous results obtained with 
antimicrobial susceptibility. The short action that this antibiotic has on bacterial cells 
can explain this scenario.  
Also, an important and unexpected result is related to the increased efficiency of 
phage phiIBB-PAC23 when used in combination with antibiotics. As in the previous 
results, the evaluation of the effectiveness of phage infection in biofilms by phage 
phiIBB-PAC23 has dictated poor results after 24 h of treatment. The combination of 
this phage with amikacin revealed interesting results with more than 1.4 log reduction 
of viable cells counts in relation to the application of these agents alone. 
Additionally, to test the combined therapy in other ratios, two antibiotics and 
phage were combined in the same solution. In literature, there are studies that show that 
the combination of beta-lactams and aminoglycosides may result in good synergy 
[13]
 
and therefore a combination of amikacin, piperacillin and phage phiIBB-PAP1 was 
used. However, after 24 h, better results have not been achieved in relation to what had 
been obtained (data not presented). 
 
Another important point is related with the stability of the phage in the presence 
of antibiotics (Figure 4.8).  
Figure 4.8: Analysis of phage viability during synergy treatment. a) phage P1 with ciprofloxacin and 
amikacin; b) phage P21 with tetracycline and piperacillin; c) phage C23 with ciprofloxacin and amikacin. 
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Counting PFU's during the incubation period of a combined solution shows that 
phages did not lose their viability during the 24 h of contact with the antibiotic solution. 
In general, after 24 h, the phage titre continued at 10
8
 PFU/ml.  
In general, using phage and antibiotics simultaneously not only against P. 
aeruginosa but also other pathogens is an emerging and promising alternative for the 
control of biofilms 
[1,14]
. Studies by Rahman M. et al (2011) showed that total 
eradication was not achieved, however the co-treatment with phage and rifampicin 
reduced the viable cells of S. aureus in biofilms by 5 log 
[7]
. Similarly, Verma et al 
(2009) demonstrated that the combination of a lytic phage and amoxicillin can be an 
alternative instead use the two therapies alone to reduce Klebsiella pneumonia viable 
cells in biofilms 
[15]
.  
On the other hand, the use of phage-antibiotic combinations can be an attractive 
option to deal with chronic infections, instead use multiple combinations of antibiotics, 
which in turn allows to an increase in multidrug resistance of bacteria and toxicity in the 
body 
[13]
. 
Nevertheless, the synergy between phage and antibiotics may be a very complex 
process since all this mechanism is not uniform, and according to the obtained results, it 
seems to be dependent of the phage and antibiotic used and also of the phage-host 
system. Furthermore, it is not easy to understand and associate which are in fact the 
variables involved in the combined effect of phage and antibiotic, since the behaviour 
against the combined treatment was not always linear between planktonic cultures and 
biofilms using exactly the same biological and chemical agents. Furthermore, synergy is 
not observed with all phages and antibiotics. Therefore, in order to understand what 
possible mechanisms are behind the synergy between phage and antibiotics, several 
factors were analysed, such as: the antibiotic susceptibility and zeta potential of LPS 
mutant phenotypes, the effect of the EPS matrix, the effect of phage growth cycle 
characteristics after exposure to antibiotics and susceptibility of antibiotic challenged 
cells to the action of endolysins. 
 
4.3.3 Antibiotic susceptibility and zeta potential of LPS mutant phenotypes 
 
In the combined assays, resistant phenotypes were found and according to 
previous results (Diana P. P. Pires, unpublished data) it is expected that this phenotypes 
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are LPS defective strains, consequently it is hypothesise that these mutants can have 
altered susceptibilities to both phages-antibiotics compared with the wild type strains. 
To confirm this hypothesis, MIC assays and potential zeta experiments were carried out 
(Table 4.3) to some LPS mutants (see description in materials and methods).  
 
Table 4.3: Zeta potential measurements for wild-type strains and its LPS derivatives mutants 
MIC (mg/l)  
Strain Potential zeta 
(mv)±SD 
Amik Cipro Piper Tetra  LPS property 
Wzy PA01  -8,27  ± 0.193 4  0,125 4 16 A+ B- 
Rmd PA01  -14,9 ± 0.961 4  0,0625 8 8 A- B+ 
Rmlc 
PA01  
-21,5 ± 0.757 2 1 4 16 A- B- 
Wbpl 
PA01  
-14,8  ± 0.173 4 0,0625 16 4 A- B- 
M2 ATCC -17,7 ± 0.964 2 0,125 8 8 A- B- 
PA01 – 
wild type 
-12.6 ± 0.7 4 0,125 16 8 Wild type; 05 (B band), A 
band LPS 
ATCC – 
wild type 
-4.43 ± 0.364 4 0,125 8 16 Wild type; 06 (B band), A 
band LPS 
 
 
The results reveal that differences in LPS structures result in different antibiotic 
uptakes by bacterial cells compared to their parental strains (Table 4.3). For example 
Rmlc and M2 are the most electronegative mutant strains and both have lower MIC 
values than the wild type strain when they were exposed to amikacin. This happens due 
to better interaction between more negative LPS and cationic antibiotics. In relation to 
piperacillin, an unexpected result was observed for strain Rmlc, because a more 
electronegative surface would dictate a higher repulsion between the cell surface and 
piperacillin that has an anionic structure. Probably these differences are due to complex 
interactions between cell surface and the surface charge of the antibiotic. Computational 
simulations have shown that electrostatics interactions between the phosphate groups 
and cations present in the oligosaccharide portion of the LPS can influence the 
conformation of the pore in the OprF protein. For example, in the absence of the 
oligosaccharide chains and cations, which happens with mutants that have both A- and 
B-bands affected, the extra-cellular loops of OprF porin will adopt a closed 
conformation, restricting the entrance to the pore 
[16,17]
. From another perspective, 
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Godfrey et al (1984) showed also that changes in the structure of LPS molecules lead to 
increases of MIC values for some Beta-lactam antibiotics 
[18]
. On the other hand, Wzy, 
one of the less electronegative strain, presents a lower MIC value in relation to wild 
type after the exposure of piperacillin. Wbpl and Rmd strains, with an intermediate value 
of potential zeta, present a lower MIC value, in relation to wild type, when expose to 
ciprofloxacin. These results suggest that the type of LPS can significantly affect the 
interaction between antibiotic and cell surface, and in some cases this can reflect the 
synergism between phage and antibiotic.  
Another factor that can influence the adsorption of antibiotics and phage 
molecules can be related with the type of serotype (O-antigen in LPS structure) present 
in the strains - see Table 4.3 for wild type strain. In the analysis made by Lam et al 
(1994), the B-band LPS molecules present in O5 strain are more filled in relation to the 
O6 strain, that only show a patchy B-band 
[19]
. The zeta potential measurements 
performed in this work show that the strain PA01 is more electronegative than the 
ATCC 10145 strain and this is in agreement with the work of Lam et al (1994). 
Possibly, in ATCC 10145 strain there is a limitation of the number of sites for amikacin 
and phage interaction, which in turn can cause co-competition between phage and 
amikacin for adsorption sites on LPS. Note that previously (Figure 4.7) it was observe 
that amikacin and phage phiIBB-PAA2 not acted synergistically.  
In general, these results suggest that the presence of LPS mutants may contribute 
to a positive configuration on the phage-antibiotic synergy.  
 
4.3.4 Biofilm biomass 
 
Another possible mechanism that can explain the perfect dualism between phage 
and antibiotic is the impact of combined treatment in the total biomass of biofilm. The 
total biomass present after antibiotic and combined treatment was measured by violet 
crystal assays (Figure 4.9).  
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Figura 4.9: Biomass quantification using Crystal Violet Staining: a) Treatment with antibiotic; b) 
combined treatment phage-antibiotic. 
 
According to the results in Figure 4.9, in general, the total biomass is 
significantly reduced (p<0.05) after the exposure to all phage-antibiotic combinations 
tested, suggesting that this treatment option potentiates biofilm matrix disruption 
rendering cells without a matrix shield become more vulnerable to antibiotics and 
phages action. In this context, it is suggested that the phages create some opening 
channels along the biofilm matrix, allowing the cells present in the structure of the 
biofilm stay in suspension, allowing a more effective action of antibiotics and phage 
themselves. 
 
b) 
a) 
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4.3.5 Effect of antibiotics on the phage growth cycle 
 
It has been described that any stimuli such as temperature, agitation or cell 
filamentation can have an important effect in the increase of protein synthesizing 
system, and consequently, in higher phage production 
[20]
. Therefore, it was important to 
realize if the presence of antibiotics could lead to changes in the parameters of the 
phage infection process. For this purpose bacteria were exposed to piperacillin to 
determine if the cell elongation, previously observed in Chapter 2, could enhance the 
phage phiIBB-PAP21s’ growth cycle characteristics (Figure 4.10). In Table 4.4 are 
presented the life cycle parameters that were obtained by performing phage OSGC. 
With these experiments it was possible compare the latency period and the period of 
increase in the average number of released phages per infected cell (burst size).  
 
 
Table 4.4: Life cycle parameters determined for phages used in this project 
Phage phiIBB- 
PA... 
Life cycle parameters 
P21 
Latent period – 50 min 
Rise period – 40 min 
Burst size – 20 PFU per infected cell 
 
P1 
Latent period – 40 min 
Rise period – 30 min 
Burst size – 72 PFU per infected cell 
 
A2 
Latent period – 40 min 
Rise period – 20 min 
Burst size – 37 PFU per infected cell 
 
C23 
Latent period – 10 min 
Rise period – 10 min 
Burst size – 4 PFU per infected cell 
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Figure 4.10: One-Step-Growth curve for phage P21 with antibiotic and without antibiotic. 
 
The presence of sub-lethal piperacillin concentrations resulted in a 2.5 fold 
greater burst size (Figure 4.10 and Table 4.4) which further helps to understand the 
synergy observed when combined with phage phiIBB-PAP21. These observations are in 
agreement with those by Ryan et al (2012) in which the burst size of coliphage T4 
increase when E. coli was exposed to sub-inhibitory concentrations of cefotaxime. 
Furthermore, Ryan also reported a decrease of 6 minutes on latent period 
[12]
. Although 
in this work there was an increase of phage burst size in cells treated with piperacillin, 
unexpectedly the latent period remained similar to the experiments performed in non-
challenged host cells.  
Overall, it seems that the bacterial SOS response to β-lactam antibiotics which 
results in cell filamentation 
[3]
, is an advantageous mechanism since it enhances phage 
production
[20,21]
. This happens because larger cells have a proportional increase of the 
protein synthesizing system 
[20]
. 
 
4.3.6 Efficacy of combined antibiotic-endolysins treatment  
 
To close the cycle of synergy between phage and antibiotics, there were also 
performed tests with (endo)lysins, enzymes that are encoded by a majority of dsDNA 
bacteriophages during the last stage of lytic cycle 
[22,23]
, to verify if this combination 
  Synergistic treatment 
69 
 
could enhance the penetration of both agents on biofilms of P. aeruginosa compared in 
this case to antibiotic or lysin alone (Figure 4.11).  
 
Figure 4.11: Reduction of cells number presented in biofilms of P. aeruginosa strain PA01 after the 
exposure to antibiotic, endolysin and endolysin in combination with antibiotics. 
 
 
With exception of amikacin, lysins alone and in combination with antibiotics 
seem to be ineffective against biofilms. One possible explanation can be related with the 
entry of antibiotics into the cells. Amikacin is the only of the studied antibiotics that 
enter into the bacterial cell by binding to the LPS structure and causing the rupture of 
magnesium bridges adjacent to LPS. This situation can enable the creation of a channel 
that can promote the entry of lysins to the cell, thereby alleviating the effect of the outer 
membrane. In the other combinations, an antagonistic effect was observed possibly due 
to a blocking of the porins channel by the endolysins itself, similarly to what happens 
with polyamines 
[24]
. Coupling a green fluorescent protein (GFP) to the endolysin 
68gpLys and observing through the microscope, could be a further step to understand 
the interaction of endolysins in the cells.  
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Contrarily to these results, Meng et al (2011) showed that the application of a 
lysin acted synergistically with several antibiotics and the final result was a maximum 
dispersal of the Streptococcus suis (gram positive) biofilm 
[25]
. Actually, these results 
prove to be in agreement with the bibliographic data, since the action of endolisins has 
been mainly directed to gram positive bacteria, due to the presence of a thick 
peptidoglycan layer. 
 
Overall, these results allow to conclude that the synergy action between phage 
and antibiotic can be affected by several factors and can be a very complex process. 
Furthermore, this analysis constitutes a great opportunity to developing additional 
studies in this area to better realize the interaction between these two agents. 
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Chapter 5: Main conclusions and Suggestions for forthcoming 
work 
 
The main objective of the present work was to analyze the process of synergy 
between phage and antibiotics against cultures and biofilms of P. aeruginosa. For this 
purpose, the isolated action of antibiotics and phages was first evaluated and after their 
combination evaluated. 
For antimicrobial susceptibility experiments, four antibiotics were used. In 
general, in spite of having determined a MIC within reference values for all antibiotics, 
in 24 h biofilms none of antibiotics led to its eradication. Ciprofloxacin was the most 
effective antibiotic in reducing the number of cells present in the biofilm and 
piperacillin showed to have a stressful effect on cells causing their elongation, and 
above all the later antibiotic had a poor bactericidal activity. 
Regarding the experiments of phage infection, the reduction of OD in planktonic 
cultures was not significantly affected by any phage concentration. In biofilms 
experiments, phages phiIBB-PAP1 and phiIBB-PAP21 appeared to be the most 
effective, with a reduction of 15-20% of the total biomass of biofilm. Nevertheless, 
during the infection process phage resistant mutants emerged leading to a lower 
efficiency in controlling biofilms of P. aeruginosa.  
In general, it can be affirmed that the individual application of phages and 
antibiotics, although disrupting the early stages of biofilm formation, do not achieve 
successful reductions of viable cell numbers in mature biofilms of P. aeruginosa. 
In the last part of the work, the combination of phages and antibiotics was 
adopted as a strategy to improve the control of P. aeruginosa biofilms. In planktonic 
cultures, the combined action resulted in MIC values within the reference range. 
Surprisingly, with the combination of phage phiIBB-PAP21 with antibiotics, the MIC 
values were significantly lower in relation to the application of antibiotics alone. In 
biofilms, the association of phage and ciprofloxacin caused a total biofilm removal and 
the concentration of ciprofloxacin needed to this eradication was drastically reduced, 
which can be an important step for in vivo assays. In addition, other interesting results 
were obtained for other combinations. For instance, although phage phiIBB-PAC23 had 
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a poor activity when applied alone, it proved to have potential effect when combined 
with all tested antibiotics, resulting in significant reductions in the number of viable 
cells present in biofilms.  
On the other hand, the synergy process that develops between phage and 
antibiotics is not linear, and it seems that several factors are involved. In this work it 
was possible to conclude that the effectiveness of combined treatments can be due to a 
higher phage burst sizes in cells exposed to antibiotics (ex. piperacillin), disruption of 
biofilm matrix by mutual action of phages and antibiotics. Besides, it was found that 
phage resistant phenotypes have in general lower MIC values and altered surface 
charges.  
In general, the application of combined treatments of phage and antibiotics for 
the control and elimination of both planktonic cells and biofilms is an successful 
approach that must be considered in the future as an alternative and a good option in 
relation to the use of phages and antibiotics alone. However, the knowledge of the 
possible variables involved in the process of synergy is a fundamental step that should 
be explored to disclose the interaction of these two agents.  
For future studies, and in order to optimize the work performed during this 
project, the following experiments are suggested: 
 Additional experiments with a sequential addition of phage and 
antibiotic. The objective is to compare with the simultaneous treatments 
performed in the present work and evaluate how the genetic diversity of a 
bacteria population evolve during the process of adaptation when exposed to 
phage and antibiotic.  
 Application of a cocktail composed of phages, lysins, 
depolymerases and antibiotics against P. aeruginosa biofilms. With this, the 
objective is to obtain a solution with a greater range of action and which is able 
to minimize the appearance of resistant phenotypes. The depolymerases would 
allow a greater diffusion of antibiotics, phage and lysins by destruction of the 
physical integrity of the biofilm matrix, exposing a higher number of cells to 
their action.  
 Directing the research for biomolecular analysis to evaluate the 
possible interactions between phages and antibiotics in biofilms to further 
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understand if the combined action of the two agents results in inactivation or 
repression of resistance genes.  
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Chapter 6: Appendixes 
 
Appendix 1: Clinical breakpoints defined by EUCAST 
 
Figures A1 and A2 present the MIC distributions for P. aeruginosa.   
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Figure A.1: Clinical breakpoints EUCAST for a) amikacin and b) ciprofloxacin against P. aeruginosa.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
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Figure A.2: Clinical breakpoints EUCAST for a) piperacillin and b) tetracycline against P. aeruginosa.  
 
 
 
 
 
 
b) 
